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PREFACE 
IRAK4 (interleukin 1 receptor associated kinase 4) is a critical component of 
TLR/IL-1R (toll like receptor/interleukin 1 receptor) signaling pathways. IRAK4 is 
recruited to active receptor complex, which is triggered by ligand engagement, via 
adapter protein MyD88 (myeloid differentiation factor 88). In receptor complex, 
IRAK4 becomes active and then activates downstream molecules leading to 
appropriate response of cells to stimulation [Martin, Wesche – BBA – 2002]. In the 
other hand, IRAK4 was reported to be involved in T cell receptor signaling and in 
phosphorylation of NADPH oxidase cytosolic factor p47phox in neutrophils which is 
completely different from known functions of IRAK4 [Suzuki et. al. – Science – 
2006; Pacquelet – Biochemical Journal – 2007]. Thus, it is likely that more not yet 
defined functions of IRAK4 exist.  
In an attempt to seek new partners of IRAK4 using the yeast two-hybrid screening, 
AUP1 (ancient ubiquitous protein 1) was identified to interact with IRAK4. This 
interaction was confirmed in HEK293RI cells by co-immunoprecipitation 
experiments. Moreover, the associations between AUP1 and many components of 
the IL-1 signaling pathway such as IL-1RI, MyD88, IRAK1, TRAF6 were found. 
AUP1 was also detected in complex with TNFR1, TRADD, TRAF2 – components 
of the TNFα pathway – as well as with the specific receptor of IL-6 cytokine IL-6Rα 
chain. Based on these findings, the aim of this study was to investigate the 
biological function of AUP1 in the signaling transductions induced by IL-1β, LPS, 
TNFα and IL-6 in cells in which AUP1 was overexpressed or silenced.  
The introduction summarizes current knowledge of AUP1 and some related respects 
of the present study and puts them into context with IL-1 and cytokine signaling.    
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1. INTRODUCTION 
1.1. Known biological functions of AUP1  
Since the identification of AUP1 in 1996, there have been not so many publications 
reporting biological functions of AUP1.  
AUP1 associates with cytoplasmic tail of αIIb subunit but not with β3 subunit of 
integrin receptor in UT7/TPO cells, a megakaryocyte-derived cell line. Integrin 
αIIbβ3 (GPIIb-IIIa) is one of the receptors on cellular surface of platelets and 
megakaryocytes. It binds to various adhesive proteins including fibrinogen, von 
Willebrand factor, vitronectin, and fibronectin. Binding of fibrinogen to αIIbβ3 leads 
to platelet aggregation and finally to thrombus formation at the injured vascular 
sites. αIIbβ3 on resting platelets does not bind soluble fibrinogen, once platelets are 
activated, conformation of the extra cellular domains of αIIbβ3 is altered and its 
ligand binding affinity is increased. This process of the inside-out signaling is 
considered to be mediated by modification of the short cytoplasmic tail of αIIb and 
β3 subunits. Besides αIIb subunit, AUP1 was shown to bind to cytoplasmic tails of 
various integrin α subunits such as α1, α2, α5, αV, αM but not with β1, β2, β3 
subunits. Full-down experiment revealed that AUP1 interacts with cytoplasmic tails 
of αIIb subunits at the conserved membrane-proximal domain which exerts a 
negative regulatory function and block αIIbβ3 in a low affinity state [Kato et.al. – 
JBC – 2002].  
In resting platelets, AUP1 was detected in a complex with αIIbβ3, Src and Syk 
(spleen tyrosine kinase) constitutively. In vitro binding study revealed that 
recombinant Syk binds directly to AUP1 and the β3 cytoplasmic tail. In platelets 
stimulated with thrombin, activated/phosphorylated Syk does not interact with 
AUP1. In vitro kinase assay of Syk in the presence or absence of AUP1 proved that 
AUP1 does not directly influence autophosphorylation or tyrosine phosphorylation 
of Syk by Src, a potent activator of Syk. These results indicate that AUP1 is an 
adaptor recruiting Syk to the αIIb cytoplasmic tail, and suggest that the αIIb – AUP1 
– Syk – β3 complex formation links αIIb and β3 cytoplasmic tails to sustain αIIbβ3 in 
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an inactive state and Syk dissociates from AUP1 after activation [Kato, Oshimi – 
Platelets – 2009]. 
AUP1 was reported to be a component of a protein complex required for dislocation 
of misfolded glycoproteins from endoplasmic reticulum (ER) [Mueller et. al. – 
PNAS – 2008]. Misfolded membrane or secretory proteins that fail to pass quality 
control in the ER are transported back across the ER membrane into the cytosol, a 
process called dislocation or retrotranslocation. In cytosol, misfolded proteins are 
degraded by the proteasome in a ubiquitin-dependent manner [Mueller et. al. – 
PNAS – 2008]. Two viral proteins encoded by human cytomegalovirus US2 and 
US11 which facilitate dislocation of newly synthesized class I MHC (major 
histocompatibility complex) heavy chains in infected cells, presumably to overcome 
the  recognition by cytotoxic T cells, have been used as models to study dislocation 
protein complex in mammalian cells [Mueller et. al. – JCB – 2006; Mueller et. al. – 
PNAS – 2008]. Derlin-1 protein was identified to be essential for the degradation of 
class I MHC molecules catalysed by US11, but not by US2 [Lilley and Ploegh – 
Nature – 2004]. Derlin-1 interacts with US11 as well as with VIMP, a novel 
membrane protein that recruits the p97 ATPase and its cofactor to dislocation 
complex [Ye et. al. – Nature – 2004]. Derlin-1 forms a complex with other member 
of Derlin family, Derlin-2, as well as HRD1 and SEL1L. HRD1 is a 
nonglycosylated ER membrane protein containing a RING domain that acts as an 
active E3 ubiquitin ligase in vitro. HRD1 participates in the degradation of ER 
proteins and protects cells from ER stress-induced apoptosis. SEL1L is predicted to 
be a type I membrane protein with five N-linked glycans [Lilley and Ploegh – 
PNAS – 2005]. Because the bulk of the SEL1L protein is predicted to be in ER 
lumen, it is possible that SEL1L first plays the role in substrate recognition and 
identification of misfolded proteins, and then recruits them to the site of dislocation. 
Knockdown of SEL1L expression by shRNA impaired US11-mediated dislocation 
of class I MHC heavy chains but not with those mediated by US2. Furthermore, 
reduction of SEL1L level also inhibited the degradation of a misfolded ribophorin 
fragment (RI332) independently of the presence of viral accessories [Mueller et. al. 
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– JCB – 2006]. In an attempt to identify more components of misfolded 
glycoprotein dislocation complex, AUP1 was discovered to associate with SEL1L. 
Overexpression of the dominant negative form of AUP1, GFP-AUP1, inhibited 
strongly US11-mediated class I MHC heavy chains dislocation and degradation. 
Although the function of AUP1 in dislocation and degradation of glycoproteins is 
obscure, its CUE domain may be involved in recruitment of another ubiquitin-
conjugating enzyme [Mueller et. al. – PNAS – 2008].  
 
1.2. Identification, characterization and cloning of novel gene aup1  
aup1 gene was identified on mouse chromosome 6 in the progress of positional 
cloning of mouse mnd2 gene whose mutation results in early onset motor neuron 
disease. In that work, Jang and coworkers found an unknown 0.7kb clone which 
could hybridize with genomic DNA from human, cat and dog. They used that 
fragment to screen mouse cDNA library by hybridization and detected five 
overlapping cDNAs spanning 1490 nucleotides with an open reading frame of 1230 
nucleotides. That gene was cloned and named aup1 (ancient ubiquitous protein 1) 
[Jang et.al. – Genomics – 1996]. Mouse AUP1 protein, containing 410 amino acid 
residues, is highly conserved to the Caenorhabditis elegans F44b9 protein with 53% 
amino acid similarity. Human aup1 gene which was identified by EST (Expressed 
Sequence Tag) database searching locates in chromosome 2p13 and encodes a 
protein with 86% amino acid sequence identity and 90% conservation with the 
mouse protein. The gene symbol aup1 reflects the evolutionary conservation of the 
protein [Jang et.al. – Genomics – 1996].  
Karpisheva and coworkers reported the cloning of cDNA of human aup1 gene and 
its genomic organization. Genomic length of the human aup1 gene is composed of 
12 exons and 11 introns spanning 3047bp with a single open reading frame of 1230 
bp [Karpisheva et. al. – Tsitologiia – 2002]. 
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 C.elegans-F44b9.5      ---------------------MASPEASSSGNTEDLRIEDLFHQKR-NEDTIAKIFSIIY 
 Mouse-AUP1             MPKDSAFPGAPAALRRWRRQRPRSPEAAAMEPPPAPGPERLFDSHRLPSDGFLLLALLLY 
 Human-AUP1             -----------------------------MELPSGPGPERLFDSHRLPGDCFLLLVLLLY 
                                                        .     * ** .:*   * :  :  ::* 
 
 C.elegans-F44b9.5      APVGLIILLIRVFLGFHTFIVACLLRKSAALRMHTLRIMCSILGIVV--EKSGHRDESAR 
 Mouse-AUP1             APVGLCLLVLRLFLGLHVFLVSCALPDS-VLRRFVVRTMCAVLGLVARQEDSGLRDHRVR 
 Human-AUP1             APVGFCLLVLRLFLGIHVFLVSCALPDS-VLRRFVVRTMCAVLGLVARQEDSGLRDHSVR 
                        ****: :*::*:***:*.*:*:* * .* .** ..:* **::**:*.  *.** **  .* 
 
 C.elegans-F44b9.5      VLCANHVSILDHLAVDILTPCLLPSVWDIPSIIRWCFGYVDLGATRGRDQLVSRAKQLLT 
 Mouse-AUP1             VLISNHVTPFDHNIVNLLTTCSTPLLNSPPSFVCWSRGFMEMD---RRVELVESLKKFCA 
 Human-AUP1             VLISNHVTPFDHNIVNLLTTCSTPLLNSPPSFVCWSRGFMEMN---GRGELVESLKRFCA 
                        ** :***: :**  *::**.*  * :.. **:: *. *::::.    * :**.  *.: : 
 
 C.elegans-F44b9.5      REQM---PLLAFPEGIITSGEKALIKFNTWCFEVSSVVQPVSVRVWRPYPWKVSVSVLGS 
 Mouse-AUP1             STRLPPTPLLLFPEEEATNGREGLLRFSSWPFSIQDVVQPLTLQVQRPL---VSVTVSDA 
 Human-AUP1             STRLPPTPLLLFPEEEATNGREGLLRFSSWPFSIQDVVQPLTLQVQRPL---VSVTVSDA 
                          .:   *** ***   *.* :.*:.*.:* *.:..****:::.*.**    ***:* .: 
 
 C.elegans-F44b9.5      SWWTDLFYFFALPFTVITVEYLPKMERRENESLEEFTARVAETLAGNLKIAVSKFGISDA 
 Mouse-AUP1             SWVSELLWSLFVPFTVYQVRWLHPIRRQLGEESEEFALRVQQLVAKELGQIGTRLTPADK 
 Human-AUP1             SWVSELLWSLFVPFTVYQVRWLRPVHRQLGEANEEFALRVQQLVAKELGQTGTRLTPADK 
                        ** ::*:: : :****  * :*  : *. .*  ***: ** : :* :*    :.:  :*  
 
 C.elegans-F44b9.5      TEAAKRLRTDRERAKKVVVREKTSPRLADPRQMDECAMRIKQSFPSFHLSAIRRDLEKTR 
 Mouse-AUP1             AEHMKRQRHPRLRPQSVQSSFPSPPSPSSDVQLTTLAHRVKEVLPHVPLNVIQRDLARTG 
 Human-AUP1             AEHMKRQRHPRL-------SFPPSPGPSPDVQLATLAQRVKEVLPHVPLGVIQRDLAKTG 
                        :*  ** *  *           ..*  :   *:   * *:*: :* . *..*.*** .*  
 
 C.elegans-F44b9.5      SQTTTVNNLKAGKISSSASDGQTGK-----------------------VTLDAGTW--RG 
 Mouse-AUP1             CVDLTITNLLEGAVAFMPEDVTEGSQSPPAPSAPKFPSSGLATPQPTALTFAKSSWARQE 
 Human-AUP1             CVDLTITNLLEGAVAFMPEDITKGTQSLPTASASKFPSSGPVTPQPTALTFAKSSWARQE 
                        .   *:.**  * ::  ..*   *.                       :*:  .:*  .  
 
 C.elegans-F44b9.5      VFDNRKWQMIEVNRQKYMNRDS---- 
 Mouse-AUP1             SLQERKQALYEYARRRFRERQAQEAE 
 Human-AUP1             SLQERKQALYEYARRRFTERRAQEAD 
                         :::**. : *  *..: :* :     
 
Figure 1.1: Position and structure of human aup1 gene in genome and amino acid sequence 
alignment of human AUP1 protein and its counterparts in mouse and Caenorhabditis elegans. 
Asterisks, amino acid identity between mammal and C.elegans; double dots, conservative 
substitutions; single dots, semi-conserved substitutions. 
Reference database: www.ncbi.nlm.nih.gov, alignment program: www.ebi.ac.uk/Tools/muscle     
 
1.3. Expression of AUP1 in cells and tissues 
The transcript of aup1 gene was detected in many tissues of adult mouse such as 
brain, fat, intestine, heart, kidney, liver, lung, muscle, ovary, pancreas as well as in 
mouse embryo [Jang et.al. – Genomics – 1996]. In human tissues, aup1 transcript is 
also expressed in leukocytes, lung, placenta, small intestine, liver, kidney, spleen, 
thymus, colon, skeletal muscle, heart and brain. With immunoblot analysis using 
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rabbit antiserum against a synthetic peptide for hAUP1, the expression of AUP1 
protein was determined as duplicate bands of ~40 kDa in many human cell lines 
(UT7/TPO, CMK, HL60, K562, U937, Jurkat, Raji, HepG2, HEK293, HeLa, 
MCF7, A547) [Kato et.al. – JBC – 2002]. 
Because of its evolutionary conservation and ubiquitous expression, AUP1 likely 
plays basic and essential roles in cellular biology [Jang et.al. – Genomics – 1996; 
Kato et.al. – JBC – 2002].  
 
1.4. Intracellular localization of AUP1 
Observation of intracellular localization of AUP1-RFP (red fluorescent protein) 
fusion protein revealed that AUP1 distributes evenly throughout the cytoplasm 
without any colocalization with Golgi apparatus or ER but not in the nucleus 
[Karpisheva et. al. – Tsitologiia – 2002; Kato et.al. – JBC – 2002]. Although it was 
reported that N-terminus of mouse AUP1 resembles the signal peptide of secreted 
proteins, human AUP1 was undetectable in concentrated culture supernatant of 
UT7/TPO cells. These findings indicated that AUP1 is a cytoplasmic protein [Kato 
et.al. – JBC – 2002]. 
However, in another study, immunofluorescence with anti-AUP1 antibody showed a 
reticular endoplasmic reticulum staining pattern and colocalization with the ER 
marker PDI. AUP1 readily cosediments with the microsomes in the absence of 
detergent and is largely resistant to extraction with alkaline sodium carbonate and 
urea [Mueller et. al. – PNAS – 2008]. These data suggest that AUP1 resides, at least 
partially, in the ER.        
 
1.5. Structure of AUP1 protein and its putative function domains 
A database search for the homologous domain structure revealed that human AUP1 
possesses three putative domains: transmembrane domain (residues 23-45), 
phosphate acyltransferase domain (PlsC, residues 90-193) and coupling of ubiquitin 
conjugation to the endoplasmic reticulum degradation domain (CUE, residues 296-
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337) [Kato et.al. – JBC – 2002; analysis programs: SMART (http://smart.embl-
heidelberg.de/); InterProScan (http://www.ebi.ac.uk/Tools/InterProScan/)].  
The presence of a putative transmembrane domain in N-terminus suggests that one 
of functions of AUP1 may carry out in close proximity of plasma or intracellular 
membrane. It is supported by the observation that AUP1 locates in ER. [Mueller et. 
al. – PNAS – 2008]      
Acyltransferase domain is typical for a superfamily of proteins involved in 
phospholipid biosynthesis. Characterized enzymes of this superfamily have either 
glycerolphosphate (GPAT, EC2.3.15), 1-acylglycerolphosphate (AGPAT, 
EC2.3.1.51), or 2-acylglycerolphosphoethanolamine acyltransferase activity 
[Neuwald – Current Biology – 1997]. Phospholipid  biosynthesis is initated with the 
acylation of glycerol-3-phosphate by GPAT to form lysophosphatidic acid (LPA), 
followed by acylation of LPA by AGPAT to form phosphatidic acid (PA) [Kato 
et.al. – JBC – 2002]. Besides to be the precursor for phospholipid biosynthesis in 
both eukaryotic and prokaryotic cells, LPA is known as an intercellular signaling 
molecule that is rapidly produced and released by activated cells, notably platelets, 
to influence target cells by acting on a specific cell-surface receptor. In addition to 
acting as an autocrine stimulator of platelet aggregation, LPA stimulates the growth 
of fibroblasts, vascular smooth muscle cells, endothelial cells and keratinocytes. 
Furthermore, it promotes cellular tension and cell-surface fibronectin binding, 
which are important events in wound repair. It was established that LPA binding to 
its G protein-coupled receptor leads to stimulation of phospholipases C and D, 
inhibition of adenylyl cyclase, activation of Ras and the downstream Raf/MAP 
kinase pathway, and tyrosine phosphorylation of focal adhesion proteins in 
remodeling of the actin cytoskeleton [Neuwald – Current Biology – 1997]. PA, 
another precursor for phospholipid biosynthesis, acts as an intracellular and an 
extracellular messenger. PA activates phospholipase C and many protein kinases 
involved in the signaling transduction of protein kinase C and Raf/MAP kinase 
pathways [West et.al. – DNA Cell Biology – 1997]. 
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In addition to possessing acyltransferase domain, the amino acid sequence of AUP1 
exhibits a homology with CUE domain (coupling of ubiquitin conjugation to the 
endoplasmic reticulum degradation domain). The CUE domain was discovered 
through bioinformatics analysis to detect homologues of proteins that regulate the 
ER-associated degradation pathway [Ponting – Biochemical journal – 2000]. Thirty 
two proteins encoded in the genome databases carry CUE domains [Shih et.al. – 
EMBO – 2003]. Function of CUE motifs was determined as monoubiquitin-binding 
domains and they are capable of promoting the ubiquitination of proteins that 
contain them [Shih et.al. – EMBO – 2003; Donaldson et.al. – Current Biology – 
2003; Hurley et.al. – Biochemical journal – 2006]. Ubiquitinlation regulates the 
activities of a diverse array of cellular proteins. Polyubiquitination in which chains 
of Lys48-linked ubiquitin are conjugated to proteins marks target proteins for 
degradation by the 26S proteasome [Shih et.al. – EMBO – 2003; Hurley et.al. – 
Biochemical Journal – 2006]. In contrast, monoubiquitination, the addition of a 
single ubiquitin  unit to a protein, is an important cellular regulatory signal. The 
characterized roles of monoubiquitination include acting as a sorting signal to direct 
protein traffic in the endocytic pathway, regulating vesicle budding machinery, 
modifying histones, regulating transcriptional machinery and controlling 
intranuclear localization. More regulatory roles for monoubiquitin are likely to exist 
[Shih et.al. – EMBO – 2003]. Previous studies reported that Tollip (Toll-interacting 
protein) and TAB2 (transforming growth factor β-activated kinase 1 (TAK1)-
binding protein 2), two functional proteins in IL-1 signal transduction pathway, 
possess CUE domain [Kato et.al. – JBC – 2002; Shih et.al. – EMBO – 2003; 
Kishida et.al. – Genes to Cells – 2005; Tian et.al. – JBC – 2007].  
Tollip was determined for the first time to pre-associate with IRAK1 (IL-1R-
associated kinase 1) and under IL-1β stimulation, MyD88 and Tollip-IRAK1 are 
recruited to IL-1RI and IL-1RAcP (interleukin 1 receptor type I and IL-1R acessory 
protein) complex. Then IRAK1 is phosphorylated/autophosphorylated and releases 
from receptor complex as well as Tollip. Overexpression and silencing experiments 
showed that Tollip may act as a silencer of IL-1 signaling [Burns et.al. – Nature – 
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2000]. Tollip also associates directly with TLR2 and TLR4 (Toll like receptor 2 and 
4) and inhibits TLR signaling by suppression of the activity of IRAK. In another 
hand, Tollip is phosphorylated by IRAK upon stimulation with lipopolysaccharide 
(LPS) or IL-1 [Zhang, Ghosh – JBC – 2002]. Tollip was reported to bind with 
phosphatidylinositol-3-phosphate (PtdIns(3)P) and phosphatidylinositol-3,4,5-
phosphate (PtdIns(3,4,5)P) in vitro. Mutation of lysine 150 residue to glutamic acid 
of Tollip abolished this binding as well as inhibition activity of Tollip with LPS-
induced NF-κB (nuclear factor kappa B) activity. Tollip-mediated inhibition being 
alleviated by wortmannin, a PI3 (Phosphoinositide 3) kinase inhibitor, implies that 
PI3 kinase may regulate Tollip function [Li et.al. – Molecular Immunology – 2004]. 
However, NF-κB as well as MAPK (mitogen activated protein kinase) signaling 
appeared normal in Tollip-deficient cells stimulated with IL-1β or the TLR4 ligand 
LPS. In contrast, the production of the proinflammatory cytokines, IL-6 and TNFα 
was significantly reduced after IL-1β and LPS treatment. Tollip therefore controls 
the magnitude of inflammatory cytokine production in response to IL-1β and LPS 
[Didierlaurent et.al. – Molecular and Cellular Biology – 2006]. Moreover, Tollip 
was shown involving in trafficking of IL-1RI from the cell surface to late 
endosomes, lysosomes and IL-1RI degradation. In Tollip-deficient cells and cells 
expressing only mutated Tollip (incapable of binding IL-1RI and ubiquitin), IL-1RI 
accumulates on late endosomes and is not efficiently degraded [Brissoni et.al. – 
Current Biology – 2006].     
TAB2 is an adapter protein that mediates activation of TAK1 in IL-1 signaling 
pathway. Overexpression of TAB2 induces JNK (c-Jun N-terminal kinase) and NF-
κB activation, whereas a dominant-negative mutant TAB2 impairs their activation 
by IL-1. IL-1 stimulates translocation of TAB2 from the membrane to the cytosol 
where it mediates the association of IL-1-dependent activated TRAF6 (tumour 
necrosis factor receptor associated factor 6) with TAK1 leading to 
autophosphorylation and activation of TAK1. Activated TAK1, in its turn, activates 
NF-κB and MAPK [Takaesu et.al. – Molecular Cell – 2000; Martin, Wesche – BBA 
– 2002]. Study in TAB2-deficient mouse embryo fibroblast revealed that TAB2 is 
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required for IL-1-induced TRAF6 ubiquitination. TAB2, with CUE domain, binds 
monoubiquitin in yeast two-hybrid system. Point mutation at critical phenylalanine 
residue to alanine or aspartic acid of CUE domain or deletion of CUE domain 
abolished NF-κB -activation mediated by TAB2 overexpression. Thus, CUE domain 
is likely important for function of TAB2 in IL-1 signaling pathway [Kishida et.al. – 
Genes to Cells – 2005].            
There is no data about the activity of acyltransferase domain as well as CUE domain 
of AUP1. However, the presence of these domains in AUP1 can provide clues to 
understand biological functions of AUP1.  
 
1.6. IL-1 and LPS signaling pathways 
The Toll like receptor / Interleukin 1 receptor (TLR/IL-1R) superfamily includes 
multiple receptors playing crucial role in innate and adaptive immunity. The TLR 
subfamily consists of 13 members that contain leucine-rich repeat motifs in their 
extracellular domain. They recognize distinct microbial patterns such as LPS, 
flagellin, viral double stranded RNA and unmethylated CpG motifs. Members of the 
IL-1R subfamily are characterized by Ig (immunoglobulin)-like structures in their 
extracellular domain that bind specifically members of the IL-1 cytokine family, 
which are involved in multiple immunological and inflammatory processes. In 
contrast to their distinct extracellular domains, all members of the TLR/IL-1R 
family (with exception of IL-1RII) are characterized by an intracellular TIR (Toll 
IL-1 receptor) domain. [Verstrepen et.al.– Cellular and Molecular Life Sciences – 
2008] 
 
1.6.1. IL-1 signaling pathway 
Upon engagement of IL-1 to IL-1RI, the coreceptor molecule IL-1RAcP (IL-1R 
accessory protein) comes to and forms the heterodimeric receptor complex by 
homotypic protein–protein interaction of the TIR domains. Presumably, the 
conformation of the TIR domains are altered and create scaffolds for MyD88 
recruitment. In this model, MyD88 associates with the TIR domains of receptor and 
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coreceptor possibly as a dimer and thus introduces death domains (DD) into the 
active receptor complex. By DD-DD interaction, IRAK1 and IRAK4, IL-1R-
associated kinase 1 and 4, are recruited to the IL-1R complex via MyD88 [Martin, 
Wesche – BBA – 2002]. Besides MyD88, there is another molecule involved in 
recruitment of IRAK1 to receptor complex: Tollip. Tollip associates with 
unphosphorylated IRAK1 most likely with the N-terminal, DD containing portion of 
IRAK1 in cytosol prior to cytokine stimulation. Upon IL-1 stimulation, preformed 
Tollip-IRAK1 complex is recruited to the receptor, which allows IRAK1 to bind 
MyD88 via its DD. IRAK4 does not bind IRAK1 directly but is recruited to 
complex by binding with MyD88. By this way, MyD88 mediates a close interaction 
of the two related IRAK molecules which is essential to allow IRAK4 to 
phosphorylate IRAK1. Through three TRAF6 interaction consensus motifs at C-
terminal, IRAK1 interacts with and recruits TRAF6 to receptor complex. [Martin, 
Wesche – BBA – 2002; Janssens, Beyaert – Molecular Cell – 2003; Verstrepen 
et.al.– Cellular and Molecular Life Sciences – 2008]  
In the receptor complex, very rapidly, IRAK4 becomes activated by intramolecular 
autophosphorylation of three residues (Thr342, Thr345 and Ser346) within its 
activation loop, which is required for optimal kinase activity of IRAK4. Active 
IRAK4 phosphorylates IRAK1 on Thr209 and Thr387 in its activation loop, leading 
to full kinase activity of IRAK1. Subsequently, IRAK1 becomes 
hyperphosphorylated in its ProST region, probably via autophosphorylation. Since 
MyD88 and Tollip only bind to non-phosphorylated IRAK1, hyper-phosphorylated 
IRAK1 is then released from MyD88 and the receptor complex, but not from the 
downstream signaling molecule TRAF6.  
However, many publications reported that kinase activity of IRAK1 is dispensable 
for IL-1 signaling toward NF-κB activation. In contrast, the role of IRAK1 as an 
adapter is critical for the formation of signaling complex consisting of MyD88, 
Tollip, IRAK1, IRAK4, TRAF6 which is crucial for IL-1 induced NF-κB activation. 
[Verstrepen et. al. – Cellular and Molecular Life Sciences – 2008; Gottipati et.al. – 
Cellular Signaling – 2008]    
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IRAK1-TRAF6 leaves receptor complex and interacts with a pre-existing TAK1 
(transforming growth factor β-activated kinase 1)-TAB1 (TAK1-binding protein)-
TAB2 (or TAB3) membrane-bound complex. TRAF6, an E3 ubiquitin ligase, then 
auto-ubiquitinates, attaching K63-polyubiquitin to itself. In this process, the E2 
conjugating complex Ubc13 and Uev1a is involved in. The ubiquitination of TRAF6 
is essential for the direct interaction of TRAF6 with TAK1-TAB1-TAB2(3) 
complex via TAB2. TAB2 and TAB3 both contain nuclear zinc finger motifs that 
interact with K63-polyubiquitin chains. TAB1 does not recognize poly-ubiquitin 
chains, but is implicated in the regulation of the kinase activity of TAK1. In this 
complex, TAK1 is activated somehow. The TRAF6-TAK1-TAB1-TAB2/3 complex 
then translocates to the cytosol, whereas IRAK1 stays at the membrane and 
becomes polyubiquitinated and degraded. [O’Neill – Immunological Reviews – 
2008; Verstrepen et. al. – Cellular and Molecular Life Sciences – 2008] 
Activated TAK1 then phosphorylates IKKβ (inhibitor of NF-κB (IκB) kinase β) in 
IKK complex thus activates this complex. In its turn, IKKβ phosphorylates the NF-
κB inhibitor IκB, leading to its ubiquitination and subsequent degradation by the 
proteasome. This allows NF-κB to translocate to the nucleus and bind to specific 
promotor sequences. Activated TAK1 also phosphorylates MKK3/4/6 (MAPK 
kinase). Activated MKKs phosphorylate and activate members of the JNK/p38 
MAPK family. These also translocate to the nucleus where they can phosphorylate 
several transcription factors of the basic leucine zipper (bZIP) family, like c-Jun and 
c-Fos. [Martin, Wesche – BBA – 2002; Janssens, Beyaert – Molecular Cell – 2003; 
Verstrepen et.al.– Cellular and Molecular Life Sciences – 2008] 
In the other hand, IRAK1 also undergoes K63-linked polyubiquination. Pellino-1 
and Pellino-3b are proposed important in this process. These proteins are E3 ligases 
and they interact with IRAK1. Importantly, their activity is greatly enhanced, at 
least in vitro, when phosphorylated by IRAK1 and IRAK4. The role of the kinase 
activity of IRAK1 and/or IRAK4 might therefore be at least initially to activate 
Pellinos, such that they can cause K63-linked polyubiquitination of IRAK1. This 
recruits NEMO to IRAK1, with NEMO binding to polyubiquitin chain. It therefore 
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appears that there are two mechanisms to activate the IKK complex, one involving 
recruitment of the complex to IRAK1 and another to TRAF6-TAK1. Both require 
recognition of K63-linked polyubiquitination, and both appear to be essential. 
[O’Neill – Immunological Reviews – 2008; Verstrepen et. al. – Cellular and 
Molecular Life Sciences – 2008] 
Another member of IRAK family, IRAK2, appears to compensate for IRAK1 at 
least partially in signaling events mediated by the IL-1R and TLR families. IRAK2 
can associate with MyD88, TRAF6 and activates NF-κB dependent reporter gene. 
IRAK2, instead of IRAK1 can also interact with TLR adaptor molecule 
Mal/TIRAP. Dominant negative IRAK2 can block Mal/TIRAP-induced signaling 
while dominant negative IRAK1 fails to do so. Thus, IRAK2 may selectively be 
recruited by Mal/TIRAP to participate in subsequent NF-κB activation. 
Furthermore, IRAK2 was shown to be involved in TRAF6 ubiquitination and NF-
κB activation [Ringwood, Li – Cytokines – 2008]. Since IRAK2 lacks kinase 
activity, it covers only adapter function of IRAK1 in IL-1R and TLR signaling 
pathway [Gottipati et.al. – Cellular Signaling – 2008]    
The fact that IL-1 and LPS induced NF-κB activation is not abrogated completely in 
TAK1 deficient cells suggests the existence of TAK1-independent pathways. 
MEKK3 (mitogen-activated protein kinase kinase kinase 3) is a good candidate 
because IL-1-induced NF-κB activation is impaired in MEKK3 deficient cells. In 
addition, IL-1-induced IκBα phosphorylation is only completely abolished when 
both TAK1 and MEKK3 are impaired. The TAK1-independent, MEKK3-dependent 
pathway involves IKKγ phosphorylation and IKKα activation. Interestingly, this 
pathway results in NF-κB activation through IκBα phosphorylation and dissociation 
from NF-κB, but does not cause IκBα degradation. Furthermore, MEKK3 interacts 
with IRAK1 and TRAF6 upon IL-1 stimulation. Protein kinase C (PKC) is also 
likely a candidate for substituting TAK1. Indeed, depletion of atypical PKC or p62, 
an atypical PKC-interacting protein, inhibits NF-κB, but not JNK activation in 
response to IL-1 or TRAF6 overexpression. In addition, p62 specifically interacts 
with TRAF6 upon IL-1 stimulation through binding to polyubiquitin chain of 
Introduction                                                                                                                           14 
 
TRAF6 [Verstrepen et. al. – Cellular and Molecular Life Sciences – 2008]. Finally, 
ECSIT (evolutionarily conserved signaling intermediate in Toll pathways) is 
another TRAF6-interacting protein that was shown to be involved in LPS- and IL-1-
induced signaling. Overexpression of a dominant-negative mutant or RNA 
interference mediated knock-down of ECSIT expression abolishes LPS- and IL-1-
mediated NF-κB activation. The exact function of ECSIT, is however, still unclear. 
[Martin, Wesche – BBA – 2002; Verstrepen et. al. – Cellular and Molecular Life 
Sciences – 2008]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Overview of IL-1 signaling pathway  
[Janssens, Beyaert – Molecular Cell – 2003] 
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1.6.2. LPS signaling pathway 
In contrast to IL-1 signaling, the introduction of LPS to TLR4 requires additional 
components. LPS in complex with LPS-binding protein (LBP) binds CD14 on the 
cell membrane, which transfers LPS to MD2 and TLR4 leading to homologous 
dimerization of TLR4. MyD88 is then recruited to TLR4 indirectly through TIR 
domain – TIR domain interaction with another adapter Mal/TIRAP (MyD88 adaptor 
like / TIR domain-containing adaptor protein). Mal contains a phosphatidylinositol 
4,5-bisphosphate (PIP2)-binding domain localizing it to the plasma membrane and a 
TIR domain in C-terminal. Upon LPS stimulation, Mal becomes tyrosine 
phosphorylated by Bruton’s tyrosine kinase (Btk) which is necessary for NF-κB 
activation by LPS in a not yet defined mechanism. In a similar way with IL-1R 
signaling, MyD88 recruits the complex of Tollip-IRAK1, IRAK4 and TRAF6 to 
LTR4 complex, but in addition, IRAK1 interacts with BCL10 (scaffolding protein 
B-cell leukemia/lymphoma 10). After the phosphorylation of IRAK1, the complex 
IRAK1-TRAF6-BCL10 is released from receptor and associates with pre-existing 
TAK1-TAB1-TAB2/3 membrane bound complex. Pellino2 also participates to the 
complex via interaction with IRAK1 and BCL10. Then BCL10-Pellino2-TRAF6-
TAK1-TAB1-TAB2/3 complex translocates to cytosol while IRAK1 is 
ubiquitinated and degraded. In cytosol, TRAF6 becomes poly-ubiquitination 
followed by the activation of TAK1 leading to activation of NF-κB and MAPK 
JNK/p38. The BCL10-interacting protein MALT1 (mucosa-associated lymphoid 
tissue 1) also participates to this process and it was shown to be essential in the 
LPS-signaling cascade towards NF-κB. [Verstrepen et. al. – Cellular and Molecular 
Life Sciences – 2008] 
Besides the MyD88-dependent pathway described above, there is another TLR4 
signaling pathway termed MyD88-independent/TRIF-dependent pathway. This 
MyD88-independent signaling pathway involves the recruitment of TRAM (TRIF-
related adapter molecule, also known as TICAM2) and TRIF (TIR domain-
containing adapter-inducing IFNβ, also known as TICAM1). Upon the engagement 
of LPS to TLR4, TRAM and then TRIF are recruited to TIR domain of TLR4. In 
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receptor complex, N-terminal portion of TRIF interacts with and activates IKK 
related kinase TBK1 (TANK-binding kinase 1) and IKKε resulting in dimerization 
and phosphorylation of the transcription factor IFN regulatory factor 3 (IRF3), 
which binds and activates type I IFN promoters in the nucleus. TRIF also initiates 
signaling toward NF-κB by interaction with, and thus activation, TRAF6. N-
terminal portion of TRIF can interact directly with TRAF6 while C-terminal portion 
of TRIF does so indirectly via RIP1 (receptor interacting protein 1). [Akira, Takeda 
– Nature – 2004; Verstrepen et. al. – Cellular and Molecular Life Sciences – 2008]  
TLR4 MyD88 dependent pathway and TRIF dependent pathway have recently been 
shown to signal from two locations. At the plasma membrane, TLR4 first induces 
Mal/MyD88 signaling. It then appears to traffic to the endosome, where it recruits 
TRAM/TRIF and initiates TRIF dependent pathway. This capacity for signaling 
from two locations appears to be unique to TLR4 among the TIR domain-containing 
receptors. [O’Neill – Immunological Reviews – 2008; Verstrepen et. al. – Cellular 
and Molecular Life Sciences – 2008] 
 
1.7. TNFα signaling pathway 
Tumor necrosis factor alpha (TNFα) is a multifunctional cytokine playing a key role 
in apoptosis and cell survival as well as in inflammation and immunity. TNFα acts 
via two distinct receptors TNFR1 and 2 (TNF receptor 1 and 2). Although the 
affinity for TNFα of TNFR2 is five times higher than that of TNFR1, the latter 
initiates the majority of the biological activities of TNFα. TNFR1 (p60) is expressed 
on all cell types, while TNFR2 (p80) expression is mainly confined to immune cells. 
The major difference between the two receptors is the death domain (DD) of 
TNFR1 that is absent in TNFR2. In contrast, TNFR2 contains consensus motifs for 
TRAF signaling proteins binding which TNFR1 does not have.  [van Horssen et.al. 
– The Oncologist – 2006; Verstrepen et. al. – Cellular and Molecular Life Sciences 
– 2008] 
TNFα, in homotrimer form, binds to TNFR1 and induces the trimerization of 
TNFR1. Silencer of death domain (SODD) protein is released and intracellular tails 
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of TNFR1 becomes docking place to recruit DD containing adapter proteins. First, 
TRADD (TNFR-associated death domain) binds to TNFR1 by DD-DD interaction 
and, in its turn, TRADD recruits TRAF2 and RIP1 (receptor interacting protein 1) 
which rapidly signal NF-κB activation. At later time, the internalization of TNFR1 
occurs followed by the dissociation of TRADD-TRAF2-RIP1 complex from 
receptor. From endosome, TNFR1 associates with another DD containing adapter 
FADD (Fas-associated death domain) which binds itself to pro-caspase-8 and 
subsequently activates this caspase. This activation initiates a protease cascade 
leading to apoptosis involving the mitochondria with caspases as key regulators. 
[van Horssen et.al. – The Oncologist – 2006; Verstrepen et. al. – Cellular and 
Molecular Life Sciences – 2008]. It is unclear how the TNFα-induced life-death 
pathway is regulated. It is possible that the life pathway is activated first leading to 
expression of NF-κB-regulated genes such as c-FLIP (cellular FLICE-like inhibitory 
protein), c-IAP1, cIAP2 (cellular inhibitor of apoptosis protein 1) which inhibit the 
death pathway. In some cases, when the NF-κB pathway is suppressed, the death 
pathway is carried out. [Muppidi et. al. – Immunity – 2004]  
In receptor complex, TRAF2, an E3 ligase, auto-ubiquitinates attaching K63-link 
polyubiquitin to itself in the assistance of E2 conjugating complex Ubc13/Uev1A. 
TRAF2 also ubiquitinates RIP1. Polyubiquitination of RIP1 is not only necessary to 
recruit TAK1, via binding to TAB2, but is also needed to directly recruit IKKγ. 
Binding of IKKγ via its NEMO ubiquitin-binding domain to K63-polyubiquitinated 
RIP1 carries IKK complex to close proximity with TAK1. TAK1 then 
phosphorylates IKKβ and activates NF-κB activation. Moreover, RIP1 initiates a 
TAK1 independent/MEKK3 dependent pathway toward NF-κB activation. Upon 
TNFα stimulation, RIP1 also recruits MEKK3, which phosphorylates IKKβ, leading 
to activation of the IKK-complex. These two pathways regulate each other’s 
activation and TAK1 is necessary for the regulation of the kinase activity of 
MEKK3.  
Upon TNFα stimulation, TRAF5 interacts with RIP1 but not with TRADD and by 
this way it also participates in TNFα signaling pathway to activate NF-κB. 
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Depletion of either TRAF2 or TRAF5 could not abolish NF-κB activation, but it is 
done when both of them are removed. This implicates that TRAF2 and TRAF5 are 
redundant in TNFα-induced NF-κB activation. [Chen – Nature – 2005; Verstrepen 
et. al. – Cellular and Molecular Life Sciences – 2008]   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Overview of TNFα signaling pathway 
[modified from van Horssen et.al. – The Oncologist – 2006] 
 
1.8. IL-6 signaling pathway 
IL-6 plays a key role in the maturation of B cells, as well being as a member of 
three cytokines (IL-6, TNFα and IL-1) that drives the acute inflammatory response. 
More recent reports have shown how dysregulation of IL-6 signaling contributes to 
inflammation-associated disease conditions, including obesity and insulin 
resistance, inflammatory-bowel diseases (IBDs), inflammatory arthritis, sepsis and 
even cancer. [Naugler, Karin – Trends in Molecular Medicine – 2008] 
Introduction                                                                                                                           19 
 
IL-6 binds specifically to IL-6Rα, non-signaling receptor, leading the recruitment 
and homodimerization of signaling receptor gp130. Interestingly, in the binding 
with IL-6, the soluble form of the IL-6Rα lacking the transmembrane and 
cytoplasmic parts is also capable of forming signal transduction complex. This is 
one of the rare situations in which a complex of cytokine and soluble receptor can 
act agonistically instead of antagonistically. [Heinrich et.al. – Biochemical Journal – 
2003]  
IL-6 signaling is initiated by JAK1 (Janus Kinase 1) [Murray – Journal of 
Immunology – 2007] that is noncovalently bound to gp130. IL-6-induced gp130 
dimerization leads to JAK1 apposition and transphosphorylation on tyrosine 
residues, releasing their catalytic activity. Active JAK1 then phosphorylates gp130 
at tyrosine residues within cytoplasmic domains. Phosphorylated tyrosines of gp130 
then provides binding sites for Src-homology-2 (SH2) domain of the STAT3 (signal 
transducers and activators of transcription) proteins [Murray – Journal of 
Immunology – 2007] leading to recruitment of STAT3 to gp130. Thus, STAT3 
proteins are located in close proximity with JAK1 and therefore be phosphorylated 
on a single tyrosine residue. Phosphorylated STAT3 form homodimer through 
reciprocal phosphotyrosine-SH2 interactions and become active and then translocate 
to nucleus resulting in gene expression program [Levy, Darnell – Nature Reviews – 
2002]. This program’s primary function is to promote growth and differentiation 
and prevent apoptosis, and includes the induction of genes encoding Bcl2, Bcl-xL, 
JunB, cFos, C/EPB, IRF-1 (interferon regulatory factor 1), TIMP (tissue inhibitor of 
metalloprotease 1), SOCS3 (suppressor of cytokine signaling 3), LPS-binding 
protein and others. The IL-6–STAT3 signal is regulated negatively by SOCS3, 
whose gene expression is also induced by STAT3 activation. [Naugler, Karin – 
Trends in Molecular Medicine – 2008] 
The IL-6 signal also activates the MAPK (mitogen-activated protein kinase) 
pathway, specifically ERK (extracellular signal-related kinase) through the JAK 
activation of SHP2 (a protein-tyrosine phosphatase). SHP2 then activates Ras, a 
GTPase leading to activation cascade of MAPK. The importance of this pathway, 
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however, has not yet to be elucidated fully, especially because most of the effects of 
IL-6 can be abolished by disrupting the STAT3 pathway. [Naugler, Karin – Trends 
in Molecular Medicine – 2008] 
 
  
        
               
 
 
 
 
          
 
                             
 
 
 
 
 
Figure 1.4: Over view of IL-6 signaling pathway 
[Heinrich et.al. – Biochemical Journal – 2003]
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2. AIM OF THE STUDY 
As mentioned in the preface, by the yeast two-hybrid screening AUP1 was 
identified to interact with IRAK4 and this interaction was also confirmed in 
mammalian cells. From this point of departure, aim of the present study was to 
identify the biological function of AUP1 in the IL-1 signaling pathway and it was 
extended to the LPS-, the TNFα- and the IL-6-activated pathways. Accordingly, the 
following objectives were addressed. 
• The interaction of AUP1 with several functional components of the IL-1 signaling 
transduction machinery. 
• The influence of overexpression of AUP1 on the IL-1β-, LPS-, TNFα-stimulated 
activation of NF-κB and the IL-6-stimulated activation of STAT3.  
• The interaction of AUP1 with the TNFα and IL-6 receptor complexes. 
• The influence of silencing of AUP1 on the IL-1β-, TNFα-stimulated activation of 
NF-κB and the IL-6-stimulated activation of STAT3. 
• Investigation of the interference of AUP1 overexpression with the IL-1 and LPS 
signaling transduction events upstream of the NF-κB activation.  
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3. MATERIALS and METHODS 
 
3.1. Materials  
 
3.1.1. Plasmids 
Table 3.1.1: List of plasmids used in the study 
 
Plasmid Encoded 
protein 
Sequence Tag Vector Source 
pMyD88-FL hMyD88 
(NM_002468.4) 
Full length 
Arg2-Pro309 
C-terminal 
FLAG 
pRK5C-FLAG A kind gift from Dr.Wesche, Tularik 
Inc., California, USA 
pFL-hTRAF6 hTRAF6 
(NM_145803.1) 
Full length 
Ser2-Val521 
N-terminal 
FLAG 
pRK5 A kind gift from Dr. Cao, Tularik 
Inc.,California,USA  
pRK5-hTollip 
C-FL 
hTollip 
(NM_019009) 
Full length 
Met1-Pro274 
C-terminal 
FLAG 
pRK5C-FLAG Dr. Christian Kollewe 
pCMV-Peli2 
N-FL 
hPellino2 
(NM_021255.2) 
Full length 
Phe2-Asp420 
N-terminal 
FLAG 
pCMV-tag2B A kind gift from Dr.Wesche, Tularik 
Inc., California, USA 
pFL-
hIRAK4wt 
hIRAK4 
(AF445802) 
Full length 
Met1-Ser460 
N-terminal 
FLAG 
pRK7N-FLAG A kind gift from Dr.Wesche, Tularik 
Inc., California, USA 
pFL-hIRAK4† hIRAK4 kinase 
inactive 
(KK213/4AA) 
Full length 
Met1-Ser460 
N-terminal 
FLAG 
pRK7N-FLAG A kind gift from Dr.Wesche, Tularik 
Inc., California, USA 
pFL-
hIRAK1wt 
hIRAK1 
(NM_001569) 
Full length 
Ala2-Ser712 
N-terminal 
FLAG 
pcDNA3-FL Dr. Johannes Knop (formerly 
Hannover Medical School) 
pFL-hIRAK1† hIRAK1 kinase 
inactive (K239S) 
Full length 
Ala2-Ser712 
N-terminal 
FLAG 
pcDNA3-FL Dr. Johannes Knop (formerly 
Hannover Medical School) 
pFL-hAUP-1 hAUP1 
(NM_181575) 
Full length 
Glu2-Asp410 
N-terminal 
FLAG 
pRK7N-FLAG Dr. Christian Kollewe 
phAUP1-FL hAUP1 
(NM_181575) 
Full length 
Met1-Asp410 
C-terminal 
FLAG 
pRK5C-FLAG Dr. Christian Kollewe 
pMyc-hAUP-1 hAUP1 
(NM_181575) 
Full length 
Glu2-Asp410 
N-terminal 
Myc 
pRK7 N-Myc Dr. Christian Kollewe 
phTNFR1 hTNFR1 
(NM_001065) 
Full length 
Met1-Arg455  
N/A pRK5 A kind gift from Dr.Kieser- 
Helmholtz Zentrum Muenchen - 
Germany 
pMyc-
hTNFR1 
hTNFR1  
(NM_001065) 
Ile22-Arg455 
without leader 
N-terminal 
Myc 
pMyc-CMV9  
mIL-2 leader 
DQ. Nguyen 
pMyc-
hTRADD 
hTRADD 
(NM_003789) 
Glu9-Ala312 N-terminal 
Myc 
pRK5N-Myc A kind gift from Dr.Kieser- 
Helmholtz Zentrum Muenchen - 
Germany  
pMyc-
hTRAF2 
hTRAF2 
(NM_021138) 
Full length 
Ala2-Leu501 
N-terminal 
Myc 
pRK7N-Myc DQ. Nguyen 
pFL-hIL-1RI hIL-1RI 
(NM_000877) 
Full length 
Lys2-Gly569 
N-terminal 
FLAG 
pFLAG-CMV-
1 
A kind gift from Dr.Wesche, Tularik 
Inc., California, USA 
phIL6R-HA hIL-6R 
(NM_000565.2) 
Full length 
Met1-Arg468 
C-terminal 
HA 
P409B A kind gift from Prof.Grötzinger – 
Christian-Albrechts Uni – Kiel – 
Germany  
phgp130-FL hgp130 
(NM_002184.2) 
Full length 
Met1-Gln918 
C-terminal 
FLAG 
pcDNA3.1 (-) 
Zeo 
A kind gift from Prof.Grötzinger – 
Christian-Albrechts Uni – Kiel – 
Germany 
p3xNFκB -Luc NFκB-dependent 
firefly luciferase 
N/A N/A pGL3-Basic N/A 
pGL3- 2M-
215Luc 
STAT3-
dependent firefly 
luciferase 
N/A N/A N/A A kind gift from Prof.Schaper – 
RWTH – Aachen – Germany  
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3.1.2. Expression plasmid cloning 
- High pure RNA isolation kit (Roche, Mannheim, Germany)  
- Reverse transcription: Oligo d(pT)18 (Fermentas #S1326S) 50µM in DEPC H2O; 
dNTP mixture 10mM for each (Fermentas #R0181); 5x buffer M-MuLV Reverse 
Transcriptase; RevertAid H Minus M-MuLV Reverse Transcriptase 200U/µl 
(Fermentas #EP0451)   
- PCR: 10x buffer Pfu DNA polymerase + MgSO4; Pfu DNA polymerase 
(Fermentas #EP0501) 
- DNA electrophoresis: 100bp DNA ladder (Fermentas #SM0321); 10x DNA-
loading buffer (5mM Tris-HCl - pH 8.0, 0.0025% Bromphenolblue, 0.0025% Xylen 
Cyanol, 5% Glycerol); 1x TAE buffer (40mM Tris, 1mM EDTA, 20mM acetic 
acid); ethidium bromide (#2218.1, Roth, Karlsruhe, Germany) solution 1µg/ml in 
1xTAE buffer.   
- DNA purification: NucleoSpin® Extract II (Macherey-Nagel GmbH & Co. KG, 
Düren Germany)  
- Restriction endonuclease digestion: BamHI and 10x buffer BamHI (Fermentas 
#ER0051), NotI (Fermentas #ER0591), SalI and 10x buffer Orange (Fermentas 
#ER0641) 
- Ligation: 10x buffer T4 DNA ligase; T4 DNA ligase 5u/µl (Fermentas #EL0011)    
- Plasmid DNA isolation kits: JETQUICK Plasmid Spin Kits; Jetstar 2.0 Plasmid 
purification Midi kit; Jetstar 2.0 Plasmid purification Maxi kit (GENOMED GmbH, 
Löhne Germany). 
 
3.1.3. Bacterial culture 
- E coli strain: XL1-Blue 
- LB medium: 171mM NaCl, 10g/L trypton (#8952.3, Roth, Karlsruhe, Germany), 
5g/L yeast extract (#2363.3, Roth, Karlsruhe, Germany); pH 7, autoclaved 
- LB agar: 1.5% bacto-agar (#5210.3, Roth, Karlsruhe, Germany) in LB medium; 
autoclaved, antibiotic added when needed 
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- 50x addditives for LB: 625mM MgCl2, 625mM MgSO4, 1M glucose; 0.2µm 
sterile filtered   
- 1000x Ampicillin: 50 mg/ml Ampicillin sodium salt (#K029.1, Roth, Karlsruhe, 
Germany) in water; 0.2µm sterile filtered 
- 1x TSS: 50mM MgCl2.6H2O, 10% Polyethylenglycol 6000-8000 (#33137, Serva-
Feinbiochemica GmbH&Co-Heidelberg), 5% DMSO (#A994.2, Roth, Karlsruhe, 
Germany) in LB medium; 0.2µm sterile filtered  
 
3.1.4. Mammalian cell culture  
- Cell lines:  
HEK293RI: human embryonic kidney 293 cell stably expressing hIL-1RI   
mouse KeratinoRI-/- : keratinocyte derived from IL-1RI knock-out mouse  
HepG2: human hepatocellular carcinoma cell 
- Medium: DMEM high glucose (#E15-009), 10% FCS (#A15-151), 2mM L-
Glutamin (#M11-004, all PAA, Coelbe, Germany) 
- 10x Trypsin/EDTA (#L11-003, PAA, Coelbe, Germany), 1x solution was 
prepared in DPBS 
- 100x Penicillin-Streptomycine (#P11-010, PAA, Coelbe, Germany) 
- Dulbecco’s phosphate buffered saline (DPBS) (#D5652, Sigma-Alrich, 
Steinheim, Germany) 
- Trypan blue 0.4% (#T8154, Sigma, Steinheim, Germany) 
- (4, 5-dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (#M2128, 
Sigma, Steinheim, Germany) 5mg/ml in PBS 
 
3.1.5. Transfection reagents: 
- Polyethylenimine (PEI) (#40,872-7, Aldrich) 1mg/ml in water pH 7 for plasmid 
transfection. 
- DharmaFECT #1 (#T-2001-01, Dharmacon, Thermo Scientific) for siRNA 
transfection. 
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3.1.6. Cell lysis and protein quantification 
- PBS: 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.76mM KH2PO4, pH 7.4 with 
HCl, autoclaved if required.  
- 10x Cao lysis buffer: 500mM HEPES (acid free), 2.5M NaCl, 200mM β-
Glycerophosphat, 50mM Na2-4-Nitrophenylphosphat.6H2O, 10mM 
Na2EDTA.2H2O. pH7.9  
- 1x Cao lysis buffer : 10% (v/v) 10x Cao lysis buffer, 10% (w/v) glycerol, 0.5% 
(w/v) IGEPAL=NP-40 (#I3021, Sigma) 
- 1x Cao lysis buffer with additives: 40µl 25x Protease inhibitors complete 
(#11873580001, Roche, Mannheim, Germany), 10µl DTT 500mM (#6908.2, Roth, 
Karlsruhe, Germany), 10µl 100x phosphatase inhibitor were added in 1ml 1x Cao 
lysis buffer. 
- 100x Phosphatase inhibitor:100mM NaF, 100mM Na3VO4, 500mM β-
glycerophosphat, 200mM Na2MoO4, 50mM Na4P2O7, pH 10 
- KE buffer: 4% (v/v) HEPES 0.5M - pH7.9, 8% (v/v) NaCl 5M, 0.2% (v/v) EDTA 
0.5M - pH8, 0.2% (v/v) EGTA 0.5M - pH7.6, 1mM DTT, 1mM PMSF (#P7626-5G, 
Sigma) 
- Bradford reagent: Bio-Rad protein assay (#500-0006, Bio Rad Laboratories, 
Munich, Germany)   
- BSA fraction V (#8076.2, Roth, Karlsruhe, Germany) 
 
3.1.7. Immunoprecipitation, kinase assay, SDS-PAGE and Western blot  
- Anti-FLAG M2 agarose beads (#A2220, Sigma, Steinheim, Germany), stored in 
PBS 50%glycerol, 0.02% NaN3, -20oC  
- Protein G sepharose beads (#17-0618-02, GE Healthcare, Freiburg, Germany), 
stored in 20% ethanol, 4oC 
- Protein A sepharose beads (#17-0974-01, Amershame), stored in 20% ethanol, 
4oC   
- 3x Laemmli buffer: 52.7mM Tris pH 6.8, 6% SDS, 30% Glycerol, 15% β-
Mercaptoethanol, 0.024% Bromphenolblue 
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- Table 3.1.2: Polyacrilamide gel (mini gel 7cmx9cm) 
Separating gel (5.5ml/gel) Components 
7% 10% 12.5% 15% 
Stacking gel 
(2ml/gel) 
- H2O 
- Tris-HCl 1,5M - pH 8,8 
- Tris-HCl 1M  - pH 6,8 
- SDS 1% 
- AA/Bis-AA 30%/0,8%  
- TEMED (#2367.1, Roth) 
- APS 40%  
2.2ml 
1.38ml 
- 
0.55ml 
1.38ml 
8µl 
8µl 
1.74ml 
1.38ml 
- 
0.55ml 
1.83ml 
8µl 
8µl 
1.28ml 
1.38ml 
- 
0.55ml 
2.29ml 
8µl 
8µl 
0.83ml 
1.38ml 
- 
0.55ml 
2.75ml 
8µl 
8µl 
1.22ml 
- 
0.25ml 
0.2ml 
0.33ml 
5µl 
5µl 
 
AA/Bis-AA: Acrylamide/Bis-Acrylamide (#3029.1, Roth, Karlsruhe, Germany) 
APS: ammonium persulfate (#A6761, Sigma) 
- Electrophoresis buffer: 192 mM Glycin, 25 mM Tris Base - pH ~8.5 -, 0.1% 
SDS. 
- Blotbuffer: 192mM Glycin, 25 mM Tris Base - pH ~8.5 -, 10% Methanol. 
- TBS/T: 20mM Tris, 137mM NaCl - pH: 7.6 with HCl -, 0.1% Tween-20. 
- PAGE ruler prestained protein ladder (Fermentas, Germany) 
- PVDF membrane (741260, Macherey-Nagel GmbH & Co. KG, Düren Germany) 
- Table 3.1.3: Primary antibodies and their dilution used in Western blotting 
 
 
 
Epitope Source Species from Dilution Buffer 
Flag (bioM2) Sigma-Aldrich F9291 Mouse 5µg/ml TBS/T 
GAPDH  Santa Cruz  sc-25778 Rabbit 1:800 5% MP in TBS/T 
Phospho-STAT3-Tyr705 Santa Cruz sc-8059 Mouse 1:100 5% MP in TBS/T 
phosphoSTAT3-Ser727 CST #9136S Mouse 1:1,000 5% MP in TBS/T 
STAT3 CST #9132 Rabbit 1:5,000 5% BSA in TBS/T 
Phospho-JNK Becton Dickinson     
BD #612540 
Mouse 1:500 5% MP in TBS/T 
JNK Becton Dickinson     
BD #610627 
Mouse 1:500 5% MP in TBS/T 
Phospho-p38  CST # 9211S Rabbit 1:1,000 5% BSA in TBS/T 
p38 CST #9212 Rabbit 1:4,000 5% BSA in TBS/T 
Phospho-IκB CST #9246 Mouse 1:2,000 5% MP in TBS/T 
IκB CST #9242 Rabbit 1:1,000 5% BSA in TBS/T 
c-Myc (clone A-14) Santa Cruz sc-789 Rabbit 1:2,000 1% MP in TBS/T 
AUP1 Sigma HPA007674 Mouse 1:10,000 5% MP in TBS/T 
IRAK1 (clone 2A9) Tularik, CA, USA Mouse 1:10,000 1% MP in TBS/T 
hIL-1RI  Rockland 109-401-
304 
Rabbit 1:2,000 5% MP in TBS/T 
HA (clone 12CA5) Roche 1583816  Mouse 1:2,000 5% MP in TBS/T 
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- Table 3.1.4: Secondary antibodies / reagents used in Western blotting 
MP: skim Milk Powder; BSA: Bovine Serum Albumin 
- ECL (enhanced chemiluminescene) kit (UP99619A, Interchim - Uptima, 
France). 
- Stripping buffer: 25mM glycin – pH 2 with HCl, 1% SDS 
- 5x Kinase Buffer: 100mM HEPES (Acid free), 750mM NaCl, 25mM MgCl2 · 
6 H2O - pH6.5 - , 25mM MnCl2 · 4 H2O 
 
3.1.8. Reporter gene assay 
- 5x Passive lysis buffer (E1941, Promega)  
- Luciferase substrate solution:  436µM D-Luciferin (Acid free – 54568, Biomol), 
436µM NaOH (Luciferin in 5 ml water + NaOH solution drop by drop), 20mM 
Tricin, 2.67mM MgSO4·7H2O, 1.07mM Magnesiumcarbonathydroxid·5H2O, 
33.3mM DTT, 530µM ATP (Disodiumsalt Grade I - A2383, Sigma), 290µM 
Coenzym A (Trilithiumsalt Dihydrat MP – 100493, Biomedicals). 
 
3.1.9. ELISA (Enzyme-Linked ImmunoSorbent Assay) 
- 0.1M sodium carbonate buffer: 8.4g NaHCO3, 3.56g Na2CO3/Litter H2O, pH 9.5 
- ELISA substrate buffer: 0.1M Na acetat, 0.1M citric acid - pH 4.9   
- ELISA substrate solution: 9ml substrate buffer + 1ml TMB solution (1mg/ml in 
DMSO) + 15µl H2O2 solution (3%) 
- 3,3’,5,5’-Tetramethyl-Benzidine (TMB) (#T2885, Sigma)  
- ELISA kits: 
human IL-8 ELISA antibody set (21339088, ImmunoTools) 
Secondary reagent Source (Concentration) Dilution Buffer 
Streptavidin-HRP conjugate  Dianova (0.5 mg/ml) 1:10,000 TBS/T 
HRP conjugated Mouse anti Rabbit 
IgG (light chain)  
Dianova (0.8 mg/ml) 1:10,000 5% MP in  TBS/T 
HRP conjugated Goat anti Rabbit IgG 
(heavy & light chain) 
Jackson ImmunoResearch  
(0.8 mg/ml) 
1:10,000 5% MP in  TBS/T 
HRP conjugated Mouse anti Goat IgG 
(heavy & light chain) 
Jackson ImmunoResearch  
(0.8 mg/ml) 
1:10,000 5% MP in  TBS/T 
HRP conjugated Rabbit anti Mouse 
IgG (heavy & light chain) 
Jackson ImmunoResearch  
(0.8 mg/ml) 
1:10,000 5% MP in  TBS/T 
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OptEIA mouseIL-6 set kit (555240, BD Biosciences) 
Transciption factor ELISA kit for NFκB-p65 (EK1120, Panomics) 
 
3.1.10. Small-interfering RNA (siRNA) and quantitative PCR  
- ON-TARGET plus huGAPDH control siRNA (#D-001830-01-05, Dharmacon 
RNAi Technologies, Thermo scientific) 
- ON-TARGETplus SMARTpool siRNA for hAUP1 (#L-012410-01-0005, 
Dharmacon RNAi Technologies, Thermo scientific)  
- ON-TARGETplus nontargeting siRNA #1 (#D-001810-01-05, Dharmacon 
RNAi Technologies, Thermo scientific) 
- siRNA buffer (20mM KCl, 6mM HEPES, 0.2mM MgCl2 - set pH 7.5 with 2M 
KOH)  
- 2x SYBR Green master mix (#AB-1166/B, Thermo Scientific) 
- ROX reference dye (Stratagene) 
 
3.1.11. Cytokines and stimulus 
- rhIL-1β was a kind gift from Dr. D. Boraschi, Institute for Biomedical 
Technology, Pisa, Italy). 
- rhTNFα was a kind gift from BASF AG, Ludwigshafen, Germany. 
- rhIL-6 was purchased from PBH (pharma biotechnologie hannover, 3000 
Hannover, Germany) 
- LPS was purchased from Difco Laboratories, USA. 
 
3.2. Methods 
 
3.2.1. Molecular biology techniques used in the cloning procedure  
First of all, mRNA encoding protein of interest was obtained from mammalian cells 
which express that protein by RNA isolation technique. mRNA was conversed to 
cDNA by reverse transcription (RT). Then, cDNA was used as template to amplify 
gene of interest using polymerase chain reaction (PCR). Size of PCR product was 
verified with agarose gel electrophoresis. Before further steps, PCR product was 
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purified to eliminate components of PCR reaction and purified PCR product was 
quantified with a spectrophotometer. Purified PCR product was digested with 
suitable restriction endonuclease enzymes. Digested product was purified again. In 
parallel, the backbone vector was also digested with the same restriction 
endonucleases and purified by agarose gel electrophoresis. The ligation was 
performed to insert digested purified PCR product of gene of interest into digested 
vector. Ligation mixture then was transformed to E coli and E coli colonies taking 
up plasmid were screened on antibiotic selective agar medium. Survival colonies of 
E coli on selective agar medium were picked up and expanded. Plasmids from E 
coli clones were isolated. The accuracy of recombinant plasmid was verified by 
digestion of plasmid clones with the same restriction endonucleases used in 
digestion of PCR product and backbone vector. Gene of interest in one correct clone 
was finally checked by sequencing.   
3.2.1.1. RNA isolation from mammalian cells 
Total RNA from mammalian cells was isolated using High pure RNA isolation kit 
(Roche). 1x106 cells in 200µl PBS were lysed by addition of 400µl Lysis/Binding 
buffer and vortexed for 15 seconds. The cell lysate was transferred to a High pure 
filter tube and centrifuged at 8000 x g for 15 seconds. The flowthrough liquid was 
discarded. 10µl of DNase I solution (18.2U/µl) in 90µl of DNase incubation buffer 
was applied on the filter and incubated for 15 minutes at room temperature to digest 
bound DNA. After DNA digestion, 500µl of wash buffer I was added to the filter 
tube and centrifuged at 8000 x g for 15 seconds. Washing step was repeated with 
500µl of wash buffer II. To remove completely wash buffer, 200µl of wash buffer II 
was applied to filter tube and then was eliminated by centrifuge at 13,000 x g for 2 
minutes. RNA bound in the filter was eluted with 50µl of elution buffer and 
centrifuged at 8000 x g for 1 minute. Isolated RNA was stored at -80oC. 
3.2.1.2. Reverse transcription         
mRNA in isolated total RNA was conversed to cDNA with reverse transcription 
procedure. A reverse transcription reaction was set up as following: 
- Total RNA: 1µg 
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- Oligo d(pT)18 50µM: 1µl 
- DEPC-treated H2O to 6.5µl 
The mixture was incubated at 70oC for 5 minutes. Other components were added to 
reaction:   
- 5x reaction buffer for M-MuLV Reverse Transcriptase: 2µl 
- dNTP mixture 10mM for each : 1µl 
The reaction was incubated at 37oC for 5 minutes. Finally, 0.5µl of RevertAid H 
Minus M-MuLV Reverse Transcriptase 200U/µl (Fermentas #EP0451) was added 
to reaction. Reaction was incubated at 42oC for 60 minutes and then at 70oC for 10 
minutes. cDNA was stored at -80oC. 
3.2.1.3. Polymerase chain reaction (PCR) for amplification of cloning target 
genes 
Polymerase chain reaction (PCR) for amplification of cloning target genes was 
established with components listed here: 
- Template: 2µl of cDNA synthesized in reverse transcription as described above 
was used as template in PCR. In other cases, 100pg of expression plasmid of the 
target protein if it had been cloned was introduced to PCR for template (Table 3.1.1) 
- Primers: 2.5µl of corresponding forward primer solution (10µM) and reverse 
primer solution (10µM) were added to reaction. Primers were designed with an 
adequately complementary sequence for target gene and a specific extra sequence 
for restriction endonuclease at 5’ end. Sequences of primers were described in Table 
3.2.1. 
- dNTP mixture 10mM for each: 1µl  
- 10x reaction buffer for Pfu DNA polymerase with MgSO4: 5µl 
- Pfu DNA polymerase 2.5U/µl (Fermentas #EP0501): 2µl 
- H2O was added to 50µl in total. 
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Table 3.2.1: Sequence of primers used in PCR for cloning target genes 
Plasmid Gene Template Forward primer (5’-3’) Reverse primer (5’-3’) Annealing 
temp.(oC) 
pMyc-
hTNFR1 
hTNFR1 phTNFR1 AAGCGGCCGCAATATA
CCCCTCAGGGGTTATT 
AAGGATCCTCATCTGAG
AAGACTGGGCGCG 
56 
pMyc-
hTRAF2 
hTRAF2 cDNA –
HEK293 
AATGTCGACAGCTGCA
GCTAGCGTGACCCC 
AAGCGGCCGCTTAGAGC
CCTGTCAGGT 
56 
Bold letters: complementary sequence for target genes  
Thermal profile for PCR with Pfu DNA polymerase was performed as following: 
- Initial DNA denaturing step: 95oC for 2 minutes 
- DNA denaturing step: 95oC for 45 seconds 
- Primer annealing step: specific temperature for each pair of primers 
listed in Table 3.2.1 was established for 30 seconds 
- Prolongating step: 72oC for 2 minutes    
- DNA denaturing step: 95oC for 45 seconds 
- Primer annealing step: specific temperature for each pair of primers 
listed in Table 3.2.1 was established for 30 seconds 
- Prolongating step: 72oC for 2 minutes and 30 seconds 
- Finishing step: 72oC for 10 minutes    
PCR products were stored at -20oC. 
3.2.1.4. Analysis of DNA with agarose gel electrophoresis 
PCR products were analysed by agarose gel electrophoresis to confirm whether they 
were in predicted size. 
10µl of PCR product was mixed with 1µl of 10x DNA loading buffer. Samples were 
loaded to 1% analysis agarose gel in 1x TAE buffer. 100bp DNA ladder (Fermentas 
#SM0321) was run with samples in the same gel. Electrophoresis was carried out at 
100mA, 100V in 1x TAE buffer. Post-electrophoresis agarose gel was stained in 
ethidium bromide solution (1µg/ml in 1x TAE) for 20 minutes. Stained DNA bands 
were visualized and recorded using Syngene system. 
 
 
 
8 cycles 
27 cycles 
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3.2.1.5. Purification of PCR products and restriction endonuclease digested 
products 
Before further steps, PCR products in correct size shown in agarose electrophoresis 
were purified to remove PCR reaction components using NucleoSpin® Extract II kit 
(Macherey-Nagel). 
1 volume of PCR product was mixed with 2 volume of NT buffer. Samples were 
loaded to NucleoSpin Extract II column which had been placed into a collection 
tube and centrifuged at 11,000 x g for 1 minute. The flowthrough was discarded. 
DNA-binding silica columns were washed with 600µl of NT3 buffer and were 
centrifuged at 11,000 x g for 1 minute. The flowthrough was removed and columns 
were centrifuged one more at 11,000 x g for 2 minutes to get rid of any residue of 
NT3 buffer. DNA bound in the silica membranes was eluted with 30µl of elution 
buffer NE, incubated at room temperature for 1 minute and centrifuged at 11,000 x 
g for 1 minute. 
Prior to insertion of target genes to backbone vector by ligation, purified PCR 
products were digested with appropriate restriction endonucleases. Digested 
products were purified again to eliminate endonucleases and small DNA fragments 
which can interfere with subsequent ligation reaction. The purification of digested 
products was performed with the same procedure applied for PCR products. 
In the case of backbone vectors, which were digested with restriction endonucleases 
as well, digested vectors were dissolved in 0.8% pure agarose gel by electrophoresis 
followed with ethidium bromide staining as described above. The bands of digested 
vectors were excised from agarose gel. Gel slices were weighed and solubilized in 
200µl of NT buffer for every 100mg of agarose gel. Gel slices were incubated in NT 
buffer at 50oC and vortexed briefly every 2-3 minutes until they are dissolved 
completely (5-10 min). Samples were loaded to NucleoSpin® Extract II column and 
the subsequent steps of purification were performed as those for PCR product 
purification. 
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3.2.1.6. Quantification of DNA and RNA with spectrophotometer 
RNA and DNA samples were diluted in 200µl of double distilled water with 
suitable dilution factor (50-100).  
200µl of diluted nucleic acid samples was applied for optical density (OD) 
measurement at wave-lengths of 260nm, 280nm and 320nm using Genesys 6 
spectrophotometer (Thermo Spectronic). The spectrophotometer was blanked with 
200µl double distiled water prior to measurement of samples. 
DNA and RNA concentration of samples was calculated as following formulars: 
DNA concentration (ng/µl) = (OD260 – OD320) x 50 x dilution factor 
RNA concentration (ng/µl) = (OD260 – OD320) x 40 x dilution factor 
Quality of nucleic acid samples was considered by the ratio between (OD260 – 
OD320) and (OD280 – OD320). This ratio should be from 1.8 to 2. 
3.2.1.7. Restriction endonuclease digestion 
A restriction endonuclease digestion reaction was carried out with 4 components 
including DNA substrate, restriction endonucleases (RE), working buffer for RE 
and double distiled water. DNA substrate was PCR product of target gene or 
backbone vector. Amount of DNA substrate was 5µg for one 50µl-reaction. DNA 
substrate was digested with two RE simultaneously. The combination of RE varied 
from reaction to reaction depending on cloning strategy of each construct. In most 
of cases, concentration of each RE was 5u/50µl-reaction. In other cases, 
concentration of RE was altered corresponding to working buffer system as 
manufacturer’s instruction. Working buffer was chosen for the optimal activity of 
both REs used in reaction according to manufacturer’s instruction. Double distilled 
water was added to fill up the reaction to 50µl. Reactions were incubated at 37oC for 
3 hours. 
Criteria of RE digestions performed in this study are listed in Table 3.2.2 
Table 3.2.2: Restriction endonucleases and working buffer for cloning  
Construct Retriction endonucleases  
(activity/50µl reaction) 
Working buffer  
pMyc-hTNFR1 NotI (10u) and BamHI (5u) 1x BamHI buffer 
pMyc-hTRAF2 SalI (5u) and NotI (5u) 1x Orange buffer 
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After ligation step for insertion of target gene to expression vector, the accuracy of 
recombinant plasmid was verified by digestion of plasmid clones with the same REs 
used in digestion of PCR product and backbone vector. 1µg of recombinant plasmid 
was digested by 1u of each RE in 10µl-reaction with suitable RE working buffer 
(Table 3.2.2). Digested products were analysed with agarose gel electrophoresis. 
Accurate recombinant clones would be cleaved into 2 DNA fragments in size of 
inserted target gene (PCR product) and digested backbone vector.      
3.2.1.8. Ligation 
To insert target gene to backbone vector, RE digested PCR product and digested 
backbone vector were mixed in a ligation reaction. Both PCR product and backbone 
vector were digested with the same REs hence they had compatible sticky ends 
which can join to each other. The ratio between PCR product and backbone vector 
was 3:1 in molar. Other components for ligation were 1µl of 10x T4 DNA ligase 
buffer, 0.4µl of T4 DNA ligase 5u/µl (Fermentas #EL0011) and double distilled 
water up to 10µl for total reaction. The ligation reaction was incubated at 22oC for 1 
hour. The ligation was transformed to E coli immediately or was stored at -20oC. 
3.2.1.9. Transformation of DNA plasmid to competent XL1-Blue E coli 
Before transformation, -80oC-reserved TSS competent XL1-Blue E coli was thawed 
slowly on ice. 1µl of ligation or 100ng of DNA plasmid was added to 50µl of 
competent XL1-Blue E coli. The transformation was mixed by pipetting and was 
incubated on ice for 30 minutes. Transformation was shocked at 42oC for 45 
seconds and then on ice for 2 minutes. 500µl of LB medium with additives 
(12.5mM MgCl2, 12.5mM MgSO4, 20mM glucose) was added to transformation. 
Transformation was incubated at 37oC for 1 hour with shaking at 500rpm. 250µl of 
transformation was plated on 1 dish of appropriate antibiotic selective LB agar and 
incubated at 37oC for overnight. Survival colonies of XL-1 Blue E coli on selective 
LB agar were picked up and expanded in 3ml of LB medium with antibiotic for 
plasmid isolation.  
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3.2.1.10. Plasmid isolation from E.Coli 
Plasmid from XL-1 Blue E coli cultured overnight in 3ml of antibiotic selective LB 
medium was isolated with JETQUICK plasmid miniprep spin kit (#400250 – 
Genomed GmbH) as manufacturer’s instruction.  
E coli cells were harvested by centrifugation at 5000 x g for 10 minutes. Medium 
was removed carefully. The bacterial pellet was resuspended with 250µl of solution 
G1 by vortexing or pipetting. 250µl of solution G2 was added to bacrterial 
suspension and mixed gently, but thoroughly, by inverting the tube several times. 
Lysis was incubated at room temperature for 5 min. For neutralization, 350µl of 
solution G3 was added and mixed gently but thoroughly, by inverting the tube to 
homogenise suspension. The mixture was centrifuged at room temperature and at 
15,000rpm for 10 minutes. The supernatant was loaded to Jetquick spin column and 
centrifuged at 13,000 x g for 1 minute. The column was washed with 500µl of 
buffer GX and centrifuged at 13,000 x g for 1 minute. The washing step was 
repeated with 500µl of buffer G4. After every centrifugation the flowthrough was 
discarded. To remove completely buffer G4, the column was centrifuged again at 
15,000rpm for 1 minute. Bound plasmid in the silica matrix was eluted with 50µl of 
70oC-preheated water, incubated for 1 minute and centrifuged at 13,000 x g for 2 
minute. 
To obtain big yield of plasmid, midiprep or maxiprep was performed using 
Jetstar2.0 plasmid midiprep kit (#210050 – Genomed GmbH) or Jetstar2.0 plasmid 
maxiprep kit (#220020 – Genomed GmbH) as manufacturer’s instruction. E.Coli in 
50µl/200µl (midi/maxi) of overnight culture was pelleted by centrifugation at 6,000 
x g for 10 minutes. After complete removal of medium, bacterial pellet was 
resuspended in 4ml/10ml (midi/maxi) of solution E1. 4ml/10ml of solution E2 
(midi/maxi) was added to bacterial suspension to lyse cells. Sample was mixed 
gently, but thoroughly, by inverting the tube several times and incubated at room 
temperature for 5 min. For neutralization, 4ml/10ml (midi/maxi) of solution E3 was 
added and mixed gently but thoroughly, by inverting the tube to homogenise 
suspension. The mixture was centrifuged at room temperature and at 12,000 x g for 
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30 minutes. The supernatant was loaded to Jetstar column which had been 
equilibrated with 10ml/30ml (midi/maxi) of solution E4, lysate was allowed to run 
by gravity flow. Column was washed with 2 times x 10ml/1 time x 60ml 
(midi/maxi) of solution E5. Bound plasmid in column was eluted with 5ml/15ml 
(midi/maxi) of solution E6. Plasmid precipitation was performed by the addition of 
3.5ml/10.5ml (midi/maxi) absolute isopropanol and centrifugation at 12,000 x g for 
30 minutes at 4oC. Plasmid DNA pellet was washed with 70% ethanol and 
recentrifuged. Plasmid DNA pellet was air dried and redissolved in suitable volume 
of 10mM Tris-HCl pH 8. Plasmid solution was stored at -20oC. 
 
3.2.2. Bacterial culture techniques 
3.2.2.1. XL1-Blue E coli culture 
Plasmid bearing XL1-Blue E coli was cultured in LB medium or LB agar plate with 
addition of appropriate antibiotic (ampicillin) for plasmid maintenance. Liquid 
culture was incubated at 37oC with shaking at 160rpm for overnight. Agar plate 
culture was incubated in an incubator at 37oC for overnight.      
3.2.2.2. Reservation of plasmid bearing XL1-Blue E coli 
750µl of overnight bacterial liquid culture was mixed with 750µl of sterile glycerol 
86%. The reservation was frozen and stored at -80oC. 
3.2.2.3. Generation of competent XL1-Blue E coli 
500µl of fresh overnight XL1-Blue E coli culture was transferred to 50ml of LB 
medium without antibiotic. Culture was incubated at 37oC with shaking at 160rpm. 
The growth of E coli was monitored every hour with optical density (OD) 
measurement at wave length 600nm. Bacteria were harvested by centrifugation at 
4oC and at 5,000 x g for 10 minutes when OD600nm value is from 0.3 to 0.4. After 
removal of medium, bacterial pellet was resuspended in 5ml of cold, sterile TSS 
solution (50mM MgCl2.6H2O, 10% Polyethylenglycol 6000, 5% DMSO in LB 
medium). 100µl of bacterial suspension was aliquoted to sterile eppendorfs. 
Aliquotes were frozen directly in liquid nitrogen and stored at -80oC. 
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3.2.3. Maintenance and culture of mammalian cells 
HEK293RI, KeratinoRI-/-, HepG2 cells were cultured in DMEM medium with the 
addition of 10% FCS and 2mM L-Glutamin at 37oC, 10% CO2 in a humidified 
incubator. Cells were seeded in 75cm2-culture flask containing 20ml of culture 
medium at suitable density and were splitted every 3-4 days. Seeding density for 
HEK293RI and HepG2 were 2x106 cells/flask and 1x106 cells/flask for   
KeratinoRI-/-.  
For splitting, cells were washed twice with sterile DPBS and treated with 2ml of 1x 
trypsin/EDTA solution for 2-5 minutes at 37oC. 8ml of full culture medium was 
added to terminate activity of trypsin. Cells were resuspended by pipetting. 20µl of 
cell suspension was stained with 20µl of trypan blue 0.4%. Alive cells which are not 
stained with trypan blue in suspension was counted using cell counting chamber. 
Appropriate number of cells was transferred to new culture flask.  
For maintainance, cell suspension was centrifuged at 500 x g for 5 minutes to 
remove culture medium. Cell pellet was resuspended at density of 2x106 cells/ml in 
FCS with the addition of 10% DMSO. 1ml (2x106 cells) of reservation was 
introduced to cryo tube. Cells were frozen at -80oC in an isopropanol-containing box 
and subsequently in liquid nitrogen. 
To thaw cells, frozen cells from liquid nitrogen were thawed immediately at 37oC. 
Reservation cells were diluted in 9ml of full culture medium and centrifugated at 
500 x g for 5 minutes to remove supernatant. Cell pellet was resuspended in 20ml of 
full culture medium and cultured as described above. 
 
3.2.4. Transient transfection 
HEK293RI, KeratinoRI-/-, and HepG2 cells were transiently transfected with 
plasmids as indicated in figure legends by using polyethylenimine (PEI) transfection 
method [Ehrhardt et. al. – Signal Trans – 2006]. A slight optimization of the PEI 
transfection protocol was performed for each cell line. To optimize the transfection, 
cells were transfected with EGFP encoding construct and percentage of EGFP 
expressing cells was monitored by FASC analysis.  
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In principle, healthy cells were seeded to 94mm-dishes in appropriate density and 
incubated overnight in culture condition. Plasmids were mixed with PEI (#40,872-7, 
Aldrich) solution (1mg/ml in water) in DMEM medium free of FCS and glutamin to 
total volume of 360µl and incubated for 10 minutes at room temperature. The 
transfection mixture was applied to cells in a 69.4 cm2 Petri dish in a total volume of 
3 ml of culture medium. After 4 hours of incubation in the incubator, 7ml of fresh 
culture medium was added to the transfected cells in the dish and cells were 
incubated until assays were performed. 
Summary of optimal transfection condition for cell lines: 
 * HEK293RI  
- Cell density: 3.6x106 cells per 69.4 cm2-culture dish with 10ml of full medium.  
- Transfection mixture: 6µl of DNA plasmid solution (1µg/µl), 324µl of medium 
FCS and glutamin free, 30µl of PEI solution (1mg/ml). 
* KeratinoRI-/- 
- Cell density: 2.5x106 cells per 94mm-culture dish with 10ml of full medium. 
- Transfection mixture: 12µl of DNA plasmid solution (1µg/µl), 288µl of medium 
FCS and glutamin free, 60µl of PEI solution (1mg/ml). 
* HepG2 
- Cell density: 2x106 cells per 94mm-culture dish with 10ml of full medium. 
- Transfection mixture: 6µl of DNA plasmid solution (1µg/µl), 306µl of medium 
FCS and glutamin free, 48µl of PEI solution (1mg/ml). 
For other plate formats, all components of transfection were altered according to a 
corresponding ratio of surface area (Table 3.2.3) 
Table 3.2.3: surface area ratio of different plate formats 
 
 94mm-dish 
(69.4cm2) 
6-well plate 
(9.6cm2) 
24-well plate 
(1.82cm2) 
96-well plate 
(0.28cm2) 
94mm-dish 
(69.4cm2) 
 
1 
 
0.14 
 
0.026 
 
0.004 
6-well plate 
(9.6cm2) 
 
7.23 
 
1 
 
0.189 
 
0.029 
24-well plate 
(1.82cm2) 
 
38.13 
 
5.27 
 
1 
 
0.154 
96-well plate 
(0.28cm2) 
 
247.86 
 
34.28 
 
6.5 
 
1 
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3.2.5. Cell lysis 
HEK293RI, KeratinoRI-/-, HepG2 cells transfected with plasmids and stimulated as 
described in figure legends were lysed as following procedure. Cells in 94-mm 
culture dish were washed twice with 10ml cold PBS and harvested with a rubber 
policeman in 500µl of 1x Cao lysis buffer with additives. Cells were incubated for 
30 minutes at 4oC with a gentle rotation. Nuclei were removed from lysate by 
centrifugation for 10 minutes at 500 x g, 4oC. Supernatant was harvested and purify 
with centrifugation for 10 minutes at 13,000rpm, 4oC to get cytosolic fraction. If 
nuclear extract is required, nuclear pellet was washed 3 times with 1x Cao lysis 
buffer without additives, supernatant was discarded by centrifugation for 10 minutes 
at 500 x g, 4oC. Then nuclear pellet was sonified in 200µl of KE buffer using a 
sonificator for 30 seconds, 5x10% intensity. Insoluble fraction was removed from 
nuclear extract by centrifugation for 20 minutes at 15,000rpm, 4oC. 
 
3.2.6. Bradford protein quantification method  
100µl of cell lysate samples diluted 1:50 or 1:100 in water were pipetted to wells of 
a flat bottom 96-well plate. 
BSA (bovine serum albumin) standard solution was prepared from stock of BSA 
(2mg/ml) by the addition of 768µl of assay diluent to 32µl of BSA stock to obtain 
800µl of BSA solution at concentration of 80µg/ml. Corresponding to sample 
dilution, assay diluent was 1:50 or 1:100 dilution in water of the lysis buffer used in 
cell lysate samples. 100µl of standard solutions from 80µg/ml to 0µg/ml (i.e. 80, 60, 
40, 30, 20, 10, 5 and 0µg/ml) were applied in duplicate to wells of the assay plate. 
Bradford reagent (Bio-Rad protein assay) was diluted 2.5 times in water. 100µl of 
diluted reagent was added to standard and sample wells. Protein concentration in 
samples was measured and calculated by an ELISA reader SPECTRAmax® 340 
PC384 (OD595nm) using the program for Bradford assay of SOFTmax PRO 4.3 LS 
software.  
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3.2.7. Immunoprecipitation and Western blot 
HEK293RI, KeratinoRI-/-, HepG2 cells transfected with plasmids and stimulated as 
described in figure legends were lysed with Cao lysis buffer. 20µl of cell lysate was 
mixed with 10µl of 3x Laemmli buffer and heated for 10 minutes at 95oC. SDS-
PAGE was performed according to the Laemmli procedure [Laemmli – Nature – 
1970] using 7.5-15% polyacrylamide gel. Proteins were electrotransferred to PVDF 
membrane (Macherey-Nagel) at 63mA (for 1 membrane 7x9cm) for 2 hours. Blots 
were blocked for 1 hour with blocking buffer (5% milk powder in TBS/T). Blocked 
blots were probed with 10ml solution of appropriate primary antibodies (as listed in 
Table 3.1.3) for overnight at 4oC on shaker. The blots were washed with TBS/T for 
3 times and incubated with 10ml solution of corresponding horseradish peroxidase 
(HRP)-conjugated secondary antibodies or HRP-conjugated streptavidin (as listed in 
Table 3.1.4) for 2 hours at room temperature. Blots were washed and subsequently 
incubated with ECL reagents (Interchim-Uptima) before exposure to 
chemoluminescence camera (INTAS). Blots were stripped with stripping buffer for 
30 minutes, blocked and reprobed with other primary antibodies if needed. 
For FLAG immunoprecipitation, 500µl of lysate from cells of 94-mm culture dish 
was incubated with 10µl of anti-FLAG M2 agarose beads (Sigma) for 18h at 4°C 
with gentle rotation. Beads were washed for 4 times with 1x Cao lysis buffer 
without additives and at last with PBS 0.1% IGEPAL. Supernatant was removed by 
centrifugation for 1 minute at 1000rpm, 4oC. Washed beads were resuspended in 
30µl of 3x Laemmli buffer and heated to 95°C for 10 minutes. Immunoprecipitated 
proteins were analysed with SDS-PAGE and Western blot as described. 
With IRAK1 and IL-1RI immunoprecipitation, the same procedure was performed 
in which 1µl anti-IRAK1 antibody (clone 2A9-Tularik) plus 10µl protein G 
sepharose (GE Healthcare) and 2µl anti-IL1RI antibody (Rockland 109-401-304) 
plus 10µl protein A sepharose (Amershame) were used, respectively, instead of anti-
FLAG M2 agarose beads.     
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3.2.8. Forced co-immunoprecipitation and kinase assay 
To determine whether AUP1 is phosphorylated by IRAK4 and IRAK1, HEK293RI 
cells were cotransfected with FLAG-tagged IRAK4 or IRAK1 and FLAG-tagged 
hAUP1 encoding construct. Cells were lysed and FLAG IP was performed using 
anti-FLAG M2 agarose beads (Sigma). FLAG-IRAKs and FLAG-AUP1 were 
forced into close proximity as described previously [Kollewe et.al. – JBC – 2004]. 
Washed immunoprecipitates were resuspended in a kinase reaction mixture 
containing 20mM HEPES - pH 6.5, 150mM NaCl, 5mM MgCl2, 5mM MnCl2, 
1µM ATP, and 1µCi of [γ-32P]ATP and incubated for 20 min at 30°C. The kinase 
reaction was stopped by heating at 95oC for 10min in Laemmli buffer. 
Phosphorylated proteins were separated by SDS-PAGE. The gels were dried, and 
autoradiographies were performed. 
 
3.2.9. Luciferase reporter gene assay 
For studying biological function of AUP1 in signaling transduction by reporter gene 
assay, HEK293RI, KeratinoRI-/- or HepG2 cells were seeded to wells of 24-well 
plate at suitable density with DMEM 10%FCS and cultured at 37oC, 10% CO2. On 
the next day, cells were cotransfected with p3xNFκB-Luc or pGL3- 2M-215Luc 
reporter gene construct and different amounts of pFLAG-hAUP1 construct, DNA 
concentration was kept constant by addition of empty vector. Transfected cells were 
either stimulated with rhIL-1β, rhTNFα, LPS, rhIL-6 for 18 hours or were left 
untreated for control. After stimulation, cells were washed with cold PBS and lysed 
with 100µl of 1x passive lysis buffer (Promega) for 30 minutes on shaker (300rpm). 
Cell debris were removed from lysate by centrifugation at 15,000rpm for 1 minute. 
For luciferase activity measurement, 75µl of luciferase substrate solution was added 
to 25µl of cell lysates. One second later, light signal was measured for 10 seconds 
by using a microplate luminometer (MicroLumatePlus LB96V; Berthold 
Technologies). 
For measurement of IL-1β- and TNFα-induced NF-κB activity by reporter gene 
assay in AUP1-knockdown HEK293RI, 6x104 HEK293RI cells were seeded to 
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wells of 24-well plate. 24 hours later, 100nM of anti-hAUP1 siRNA or scramble 
siRNA was transfected to cells. 44 hours post-transfection, cells were transfected 
with p3xNFκB-Luc reporter gene construct (2µg plasmid /3.6x106 cells) by PEI 
method. Once transfection done (in 4 hours), cells were stimulated either by 
100pg/ml rhIL-1β or 10ng/ml rhTNFα for 8 hours or left untreated for control. After 
stimulation cells were lysed with 100µl of passive lysis buffer for 30 minutes with 
gentle shaking (300rpm). Cell debris were removed by centrifugation at 15,000rpm 
for 1 minute. Luciferase activity in lysates was measured as described above. 
The same procedure was applied for determination of IL-6-induced activation of 
α2M-luciferase reporter gene in AUP1-knockdown HepG2 cells.      
 
3.2.10. Measurement of cytokine production by Enzyme-Linked 
ImmunoSorbent Assay (ELISA) 
HEK293RI or KeratinoRI-/- cells were seeded to wells of 24-well plate at suitable 
density the day before transfection. Cells were transfected with different amount of 
pFLAG-hAUP1 construct by PEI method. DNA concentration was kept constant by 
addition of empty vector. On the next day, transfected HEK293RI and KeratinoRI-/- 
cells were stimulated by 100pg/ml rhIL-1β, 10ng/ml rhTNFα and 100ng/ml LPS, 
respectively, for 8 hours. Supernatant was harvested; hIL-8 or mIL-6 in supernatant 
was measured by ELISA using a set of anti-hIL-8 capture and detection antibodies 
(Immuno Tools) or OptEIA mIL-6 set kit (BD Biosciences). 
ELISA was performed according to manufacturer’s instruction. In general, ELISA 
plate was coated overnight at 4oC with 100µl of capture antibody diluted in 0.1M 
sodium carbonate buffer pH 9.5 at recommended concentration. Coating buffer was 
removed and plate was washed with washing buffer (PBS with 0.05% Tween-20). 
Then, plate was blocked with 200µl of blocking buffer (10%FCS or 5%BSA in PBS 
for mIL-6 ELISA or hIL-8 ELISA, respectively) for 1 hour at room temperature. 
After washing step to remove blocking buffer, 100µl of standard and sample 
solutions were applied to proper wells. Standard was diluted in series of 2 times in 
DMEM medium 10% FCS. The highest concentration was 300pg/ml and 1000pg/ml 
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for rhIL-8 (Biosource) and rmIL-6 standard, respectively. Sample supernatant was 
either diluted 5 times in DMEM 10%FCS for the case of IL-1β-stimulated 
HEK293RI or undiluted for TNFα-stimulated HEK293RI and LPS-stimulated 
KeratinoRI-/-.  
With hIL-8 ELISA, after 1 hour incubation with standard and samples, plate was 
washed and 100µl of detection biotin-conjugated antibody diluted in assay diluent 
(1%BSA, 0.05% Tween-20 in PBS) at recommended concentration was added. 
After incubation with detection antibody for 1 hour, plate was washed. HRP-
conjugated streptavidin solution in assay diluent was applied to wells for 30 
minutes.  
With mIL-6 ELISA, after 2 hours incubation with standard and samples, plate was 
washed. 100µl of working dectector including detection biotin-conjugated antibody 
and HRP-conjugated streptavidin in assay diluent (10% FCS in PBS) was added for 
1 hour.  
In both cases, after the last washing step to get rid of unbound HRP-conjugated 
streptavidin, 100µl of substrate solution (90mM Na acetat, 90mM citric acid, 
0.1mg/ml TMB, 0.0045% H2O2) was introduced to wells. Plate was incubated for 
20-30 minutes in dark before the addition of 50µl H2SO4 1M to stop reaction. 
Cytokine concentration was measured using ELISA reader (SPECTRAmax® 340 
PC384) and SOFTmax PRO 4.3 LS software. 
For measurement of IL-1β/TNFα-induced IL-8 production from AUP1-knockdown 
HEK293RI cells, 6x104 HEK293RI cells were seeded to wells of 24-well plate. 24 
hours later, cells were transfected with 100nM of anti-hAUP1 siRNA or scramble 
siRNA. 48 hours post-transfection, cells were stimulated either by 100pg/ml rhIL-1β 
or 10ng/ml rhTNFα for 8 hours or were left untreated for control. Supernantant was 
harvested and hIL-8 ELISA was performed as described above.   
 
3.2.11. MTT assay 
To check whether AUP1 overexpression has an impact on cell viability, 0.5x106 
HEK293RI cells or 0.35x106 KeratinoRI-/- cells were plated to wells of 6-well plate 
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and incubated under culture conditions. On the next day, cells were transfected with 
pFLAG-hAUP1 construct in increasing amount. DNA concentration was kept 
constant by addition of empty vector. Transfected cells were trypsinized and 
reseeded at density of 0.5x105 cells per well of 96-well plate. HEK293RI and 
KeratinoRI-/- cells were stimulated by 100pg/ml rhIL-1β, 100ng/ml LPS, 
respectively, for overnight or were left unstimulated. Cell viabilities of HEK293RI 
and KeratinoRI-/- were determined by MTT method. 
20µl of MTT solution (5mg/ml in PBS) was added to cells in wells of 96-well plate 
containing 200µl of culture medium. Cells were incubated with MTT for 4 hours at 
culture condition. MTT medium was removed carefully from wells and 100µl of 
isopropanol with 5% formic acid was added. Optical density reflecting 
mitochondrial activity and thus indirectly quantity of cells in wells was measured 
with an ELISA reader (SPECTRAmax® 340 PC384) at wave length 570nm.    
 
3.2.12. Detection of DNA-binding activity of NF-κB-p65 
3.6x106 HEK293RI cells or 2.5x106 KeratinoRI-/- cells were seeded to 94mm-
culture dishes and incubated overnight in culture condition. 6µg or 12µg of pFLAG-
hAUP1 was transiently transfected to HEK293RI or KeratinoRI-/-, respectively. At 
the same time, instead of pFLAG-hAUP1 plasmid, empty vector was transfected to 
cells for control. 24 hours later, transfected HEK293RI and KeratinoRI-/- cells were 
unstimulated or stimulated by 5ng/ml rhIL-1β and 1µg/ml LPS, respectively, for 
different times from 5 to 180 minutes. After stimulation, cells were lysed in Cao 
lysis buffer and nuclear extracts were obtained in KE buffer. Activated NF-κB-p65 
in nuclear lysates was determined by binding activity to κB-consensus sequence 
DNA probe using Panomics’TF ELISA kit (EK1120) as manufacturer’s instruction. 
In brief, protein concentration of nuclear extracts was quantified with Bradford 
method and samples were diluted with nuclear extract dilution buffer to 
concentration of 2µg protein/µl. 10µl of diluted nuclear extracts were mixed with 
40µl binding buffer master mix containing biotin-conjugated κB-consensus 
sequence DNA probe in wells of 96-well plate. For the binding of activated NF-κB-
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p65 to DNA probe, samples were incubated for 30 minutes at room temperature 
with gently rocking the plate (150rpm). The binding complex was transferred to 
streptavidin coated assay plate and incubated at room temperature for 1 hour 
rocking the plate gently (150rpm). Plate was washed with washing buffer to remove 
unbound molecules. 100µl of a specific anti-p65 antibody solution (1/200 in 
antibody dilution buffer) was added to wells and incubated for 1 hour. In this step, 
bound NF-κB-p65 in wells was recognised by anti-p65 antibody. After washing 
step, 100µl of HRP-conjugated secondary antibody solution (1/200 in antibody 
dilution buffer) which bind to anti-p65 primary antibody was introduced to wells of 
assay plate. 1 hour later, plate was washed and 100µl of substrate solution (90mM 
Na acetat, 90mM citric acid, 0.1mg/ml TMB, 0.0045% H2O2) was added to wells. 
Plate was incubated for 5-15 minutes in dark before the addition of 100µl of stop 
solution. Optical density reflecting quantity of bound NF-κB-p65 was measured 
with an ELISA reader (SPECTRAmax® 340 PC384) at wave length 450nm. 
 
3.2.13. Small-interfering RNA (siRNA)–mediated knockdown of AUP1 
Small-interfering RNA (siRNA)–mediated knockdown of AUP1 was performed 
using ON-TARGETplus SMARTpool siRNA for hAUP1 (L-012410-01-0005 – 
Dharmacon RNAi Technologies – Thermo scientific) and ON-TARGETplus 
nontargeting siRNA #1 (D-001810-01-05 – Dharmacon RNAi Technologies – 
Thermo scientific) was used as scramble siRNA control. Anti hAUP1 siRNA pool 
consists of four siRNAs for target sequences 
GCACUAUAUGAAUACGCAA;GCAGAUUCGUAGUGCGGAC;GAGCACAU
GAAGCGACAAA; CGACCACAACAUAGUCAAU. siRNA transfection was 
carried out according to manufacturer’s instruction with a slight optimization. 24 
hours before transfection, 6x104 HEK293RI or HepG2 cells were seeded to wells of 
24-well plate in 0.5ml of DMEM medium containing 10% FSC, 2mM L-glutamin. 
25µl of anti-hAUP1 siRNA solution or scramble siRNA solution (2µM in siRNA 
buffer) was mixed with 2µl of transfection reagent DharmaFECT #1 (T-2001-01, 
Dharmacon, Thermo Scientific) in 73µl of DMEM medium FCS/Glutamin free to 
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total volume of 100µl. Transfection mixture was incubated for 20 minutes at room 
temperature. 400µl of full DMEM medium was added to transfection mixture and 
mixed gently by pipetting. The whole transfection medium (500µl of 100nM 
siRNA) was applied to each well of 24-well plate which had been removed culture 
medium. Cells were incubated at 37oC, 10% CO2 until assays. 
For AUP1 mRNA analysis, 24 hours post-transfection, cells were harvested and 
total RNA from cells was isolated using High pure RNA isolation kit (Roche). 
cDNA was obtained from 1µg of total RNA by reverse transcription. Amount of 
AUP1 mRNA in anti-AUP1 siRNA transfectant, scramble siRNA transfectant and 
mock control were determined and compared using quantitative PCR. 
For AUP1 protein analysis, 48 hours post-transfection, cells were harvested and 
lysed in 35µl of Cao lysis buffer with additives. AUP1 protein in lysates was 
analysed with SDS-PAGE and Western blotting using anti-AUP1 antibody. 
 
3.2.14. Quantitative PCR (qPCR)  
To identify siRNA-mediated AUP1 silencing efficiency in mRNA level, qPCR was 
performed with RNA samples derived from HEK293RI or HepG2 cells transfected 
with hAUP1 siRNA pool and scramble siRNA. First of all, mRNA was conversed to 
cDNA with reverse transciption step using oligo(dT) priming as described before 
(part 2.2.1.2) and then cDNA products were applied for qPCR. qPCR reaction for 
quantification of AUP1 mRNA included following components: 6µl of 2x SYBR 
Green master mix (AB-1166/B, Thermo Scientific), 4µl of 3x primer mixture, 2µl of 
mixture of template and reference dye ROX. Working concentration of forward 
primer (hAUP1 201F - GACCATGTGTGCGGTGCTA) and reverse primer 
(hAUP1 353R - CTATTGAGTAGAGGGGTGCTACA) were 150nM and 600nM, 
respectively. Thus, 3x primer mixture consisted of 450nM of forward primer and 
1800nM of reverse primer. The mixture of template and reference dye ROX 
contained 0.5ng/µl of total RNA in cDNA form and 0.18µM of ROX. Therefore, 
12µl of one qPCR reaction finally consisted of 1ng RNA template in cDNA form 
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and reference dye ROX at concentration of 0.03µM. Each RNA sample was 
performed qPCR in triplicate. 
For normalization, hGAPDH mRNA – a house keeping gene – in each RNA sample 
was quantified as an internal control in parallel with AUP1 mRNA quantification. 
qPCR reaction components for GAPDH were the same to those of AUP1 except the 
specific primers for GAPDH. Working concentration of GAPDH forward primer 
(mGAPDH 301F - ACCACCATGGAGAAGGC) and reverse primer (mGAPDH 
534R - GGCATGGACTGTGGTCATGA) were 600nM and 150nM, respectively. 
Notably, this pair of primers mGAPDH 301F and mGAPDH 534R was designed for 
mouse GAPDH but they also work with human GAPDH.  
Thermal profile for qPCR procedure was  
95oC for 15 minutes: 1 cycle 
95oC for 30 seconds and 60oC for 1 minute: 40 cycles 
A single fluorescence reading was obtained at the end of every cycle. 
After amplification, the specificity of amplified product was confirmed with 
melting/dissociation curve.  
qPCR experiments were carried out with Stratagene Mx3005PTM system and results 
were analysed with MxPro software.  
Primers for qPCR of hAUP1 and GAPDH were selected from primer database 
http://pga.mgh.harvard.edu/primerbank/ and http://mouseprimerdepot.nci.nih.gov, 
respectively, and custom synthesized (Sigma).  
The working concentration of primers and templates were defined in initial 
optimization steps for every target gene. At first the optimal primer concentration 
were defined by analyzing various concentrations (150, 300 and 600nM) of forward 
and reverse primers with 10ng of template. Primer concentrations with minimum 
cycle threshold (ct) and single amplification product (based on dissociation curve) 
were considered optimal. The second optimization was to determine optimal 
template amount by analysing the various amounts of template (10ng to 
0.156ng/reaction, it was obtained with 1:1 serial dilution from maximum to 
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minimum) and plotting the standard curve. The optimal template amount was 
chosen in range which generates a standard curve having 90-110% efficiency.   
 
3.2.15. Statistical analysis 
The data was analysed using Excel software, from Microsoft Office 2001. The 
quantitative PCR data was analyzed using MxPro software (stratagene, USA) 
provided with the thermal cycler.  
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4. RESULTS 
4.1. AUP1 associates with many components of IL-1 signaling pathway 
The original point of departure of the present study was to search for new partners 
of IRAK4 which seems to exert till unknown functions [Suzuki et. al. – Science – 
2006; Pacquelet – Biochemical Journal – 2007]. To approach this question, the yeast 
two-hybrid system was applied using Matchmaker library construction & screening 
kits (Clontech). In brief, a cDNA library derived from human placenta tissue was 
constructed and screened in yeast system for protein-protein interaction in which 
hIRAK4 was used as the bait protein. Analysis of screening results revealed novel 
partner proteins of IRAK4 AUP1 being one of them (C. Linke, C. Kollewe & M.U. 
Martin, unpublished data). 
The interaction of AUP1 and IRAK4 was confirmed in HEK293RI cells by co-
immunoprecipitation (IP) experiments. In these interaction studies, several others 
components of the IL-1 signaling pathway were also examined for interaction with 
AUP1 as depicted in Figure 4.1.  
These co-IP experiments demonstrated that AUP1 not only associates with IRAK4 
but also with IRAK1. This interaction was seen only in the cases of kinase inactive 
IRAK4 and IRAK1 mutants but not with enzymatically active wild type forms. This 
implicates that the kinase activity or phosphorylation state of IRAK molecules may 
interfere with their interaction with AUP1. In addition to IRAK molecules, AUP1 
was found to associate with other components of the IL-1 signaling transduction 
machinery including MyD88, TRAF6, Tollip. However, AUP1 did not interact with 
all molecules known to participate in IL-1 signaling, thus no interaction was 
observed e.g.with Pellino2 (Figure 4.1). 
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4.2. AUP1 associates constitutively with IL-1RI and dissociates partially 
from IL-1RI upon IL-1β stimulation  
The association of AUP1 with MyD88, Tollip, IRAK, TRAF6 which are 
components of active IL-1RI complex implicates that AUP1 may interact with IL-
1RI as well. To clarify this, IL-1RI was immunoprecipitated, using anti-IL-1RI 
antibody, from HEK293RI cells which overexpressed AUP1. Before lysis and 
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Figure 4.1: AUP1 associates with components of IL-1 signaling pathway as demonstrated by 
co-immunoprecipitation experiments. 
(A) HEK293RI cells were cotransfected with constructs encoding  Myc-tagged hAUP1 and either 
FLAG-tagged hMyD88, hTRAF6, hTollip, hPellino2, IRAK4 wildtype (WT), or IRAK4 kinase 
inactive (†) or an empty vector for control of unspecific binding. On the next day cells were lysed 
and FLAG-tagged proteins were immunoprecipitated (IP). Co-immunoprecipitated AUP1 was 
identified by Western blot (WB) using an anti Myc-epitope specific antibody. Susbsequently, the 
membrane was stripped and reprobed with an anti FLAG-epitope specific antibody. For control of 
AUP1 overexpression, cell lysates were separated by SDS-PAGE followed by Western blot using 
anti Myc-epitope antibody.             
(B) HEK293RI cells were cotransfected with plasmids encoding FLAG-hAUP1 and either FLAG-
IRAK1 WT or FLAG-IRAK1 kinase inactive. On the next day, an IP was carried out from cell 
lysates using the anti-IRAK1 antibody clone 2A9 in combination with protein G sepharose. Co-
precipitated AUP1 and FLAG-IRAK1 were detected with Western blot using anti-AUP1 antibody 
and anti FLAG-epitope antibody, respectively. Overexpression of AUP1 in lysates was confirmed 
with Western blot using anti-AUP1 antibody.  
Data shown is one representative experiment out of a series of three with comparable results. 
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immunoprecipitation cells were left untreated or stimulated with IL-1β in order to 
initiate formation of the signaling IL-1RI complex.  
AUP1 was found in association with IL-1RI constitutively in untreated cells, 
indicating that IL-1RI – AUP1 complexes may pre-exist. Stimulation of cell with 
IL-1β for 15 minutes resulted in a partial dissociation of AUP1 from IL-1RI (Figure 
4.2-upper panel). As the total amount of cellular AUP1 remained constant in the cell 
in this time frame, the possibility that AUP1 was degraded upon IL-1 stimulation 
could be excluded (Figure 4.2-lower panel).  
  
 
 
 
 
 
 
 
 
 
 
4.3. AUP1 can be phosphorylated by IRAK4 and IRAK1 
The interaction of AUP1 and IRAK4 or IRAK1 was identified only with kinase 
inactive IRAK mutants but not with wild type forms (Figure 4.1). This suggested 
that kinase activity of IRAK4 and IRAK1 may play role in the interaction of them 
with AUP1. It was reported previously that IRAK1 interacts with Tollip and 
phosphorylates Tollip [Zhang, Ghosh – JBC – 2002]. Thus, it was interesting to 
know whether AUP1 serves as a substrate for IRAK4 and IRAK1. Since AUP1 was 
not seen in complex with wild type IRAK4 and IRAK1, forced co-IP assays 
[Kollewe et.al. – JBC – 2004] were performed using anti-FLAG M2 beads to bring 
FLAG-tagged AUP1 and FLAG-tagged IRAK4 or IRAK1 into close proximity on 
the beads. The washed beads were then subjected to an in vitro kinase assay.  
IL-1β                0       0       5      15min 
IP-antibody       -       +      +      + 
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WB: anti AUP1 
Figure 4.2: AUP1 is constitutively associated 
with IL-1RI and dissociates partially from the 
receptor complex upon IL-1β stimulation 
HEK293RI cells were cotransfected with 
constructs encoding Myc-hAUP1 and FLAG-
hIL-1RAcP. On the next day, transfected cells 
were either stimulated with 10ng/ml rhIL-1β for 
0, 5, and 15min. Cells were lysed and IL-1RI IP 
was peformed using anti-hIL-1RI antibody and 
protein A sepharose. Co-precipitated AUP1 and 
IL-1RI were detected with Western blot using 
anti AUP1 and anti IL-1RI antibodies. 
Overexpression of AUP1 in lysates was 
confirmed with Western blot.  
Data shown is one representative experiment out 
of a series of three with comparable results. 
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In these forced co-IP assays IRAK4 and IRAK1 appeared as strongly 
autophosphorylated bands (Figure 4.3-upper panel). In addition, phosphorylated 
bands corresponding at the expected size of AUP1 were detected. They were easily 
seen when AUP1 was phosphorylated by IRAK4 (left panel) and much weaker, 
when AUP1 was forced together with IRAK1 (right panel). It was irrelevant where 
the epitope tag was expressed in the AUP1 molecule, both N- and C-terminally 
tagged AUP1 proteins were accepted as kinase substrates. Regarding the relation of 
the amounts of protein (shown in Figure 4.3 lower panel) one must conclude that 
AUP1 is not a very good substrate for IRAK-1. In addition, it cannot be excluded 
that the phosphorylation of the AUP1 molecules co-immunoprecipitated with 
IRAK1 was indeed phosphorylated by IRAK4 as IRAK4 also co-precipitates with 
IRAK1 due to death domain-death domain interactions.            
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Figure 4.3: AUP1 was phosphorylated by IRAK4 and IRAK1 in forced co-IP assay 
HEK293RI cells were cotransfected constructs encoding FLAG-tagged IRAK4 or IRAK1 and C 
or N-terminal FLAG-tagged hAUP1 as indicated. Cells were lysed and FLAG IP was performed. 
Beads with bound IRAK and AUP1 molecules were subjected to in vitro kinase assay. Proteins 
were separated by SDS-PAGE followed by auto-radiography. The expression of proteins in cell 
lysates was verified by Western blot using an anti FLAG-epitope specific antibody.    
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4.4. AUP1 overexpression impaired IL-1β and TNFα-induced activation 
of NF-κB in HEK293RI cells  
As described above AUP1 associates with IL-1RI constitutively and partially 
dissociates from the receptor upon IL-1β stimulation. AUP1 also interacts with 
many components of the IL-1 signaling pathway. In addition, AUP1 can be 
phosphorylated by IRAK4 and IRAK1 in the receptor complex. Taking into 
consideration all these findings, it was tempting to speculate that AUP1 may play a 
regulatory role in the IL-1 signaling pathway.  
In order to access the biological function of AUP1 in IL-1-mediated signaling, 
principally two approaches can be taken. First, it can be investigated how 
overexpression of AUP1 affects IL-1 signaling and second, it can be ascertained 
what happens to IL-1 signaling if AUP1 is not available (silencing or knock-down)  
To investigate effects of AUP1 overexpression, HEK293RI cells were transfected 
with increasing amounts of hAUP1 encoding construct together with a luciferase 
reporter gene (construct encoding for 3xNFκB-Luc) to measure the central 
transcription factor activated by IL-1. Transiently transfected cells were stimulated 
with IL-1β and the activation of NF-κB in the IL-1β signaling pathway was 
estimated by luciferase reporter gene assay. In parallel, transfected cells were also 
stimulated with TNFα to clarify whether AUP1 was specific to IL-1 signaling or 
not.      
The result showed that overexpression of AUP1 in HEK293RI partially inhibited 
IL-1β-induced activation of NF-κB in a dose-dependent manner (Figure 4.4 – grey 
bars). If cells were stimulated with TNFα, a cytokine that utilizes a discrete receptor 
complex but also addresses the NF-κB-pathway, increasing concentrations of AUP1 
also reduced NF-κB activation, demonstrating that this effect was not specific for 
the IL-1 pathway (Figure 4.4 – black bars).  
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4.5. AUP1 overexpression reduced LPS-stimulated activation of NF-κB in 
KeratinoRI-/- cells 
Lipopolysaccharide (LPS) stimulates cells through Toll-like receptor 4 (TLR4), a 
member of TLR/IL-1 receptor family, which shares many components with the IL-1 
signaling pathway to transduce signals and finally activates MAPKs (mitogen 
activated protein kinases) and the NF-κB transcription factor. [Janssens, Beyaert – 
Molecular Cell – 2003; Akira, Takeda – Nature – 2004]  
Since AUP1 overexpression interfered with IL-1β signaling, it may also interfere 
with LPS signaling. To clarify this, a keratinocyte cell line derived from an IL-1RI 
deficient mouse was utilized. This KeratinoRI-/- cell line responds to LPS. In 
Figure 4.4: AUP1 overexpression impaired IL-1β and TNFα-induced activation of NF-κB 
in HEK293RI 
1x105 HEK293RI cells/well were seeded in a 24-well plate and cultured overnight. Cells were 
cotransfected with the 3xNFκB-Luc construct and different concentrations of a construct 
encoding FLAG-hAUP1 as indicated. Total DNA concentration was kept constant at 6µg 
DNA/3.6x106 cells by addition of empty vector. Transfected cells were either stimulated with 
100pg/ml rhIL-1β, 10ng/ml rhTNFα or were left untreated. 18 hours later, cells were lysed and 
luciferase activity in cell lysates was measured. Depicted is fold induction calculated by dividing 
relative light unit (RLU) values of stimulated samples by the RLU values of unstimulated 
controls. Data shown are triplicates of one representative experiment out of a series of three with 
comparable results. Lower panels: control of protein expression of FLAG-hAUP1 in cell lysates 
and GAPDH loading control. 
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addition, interfering IL-1 signals, e.g. from endogenously produced IL-1, could by 
excluded as this cell line lacks the IL-1RI molecule. As mentioned above, NF-κB 
activation is a hallmark of the signaling pathways initiated by LPS. Therefore, NF-
κB-luciferase reporter gene assay was applied to determine LPS-induced activation 
of NF-κB in KeratinoRI-/- which overexpressed increasing amounts of AUP1.  
Overexpression of AUP1 in KeratinoRI-/- cells impaired LPS-induced activation of 
NF-κB in a dose-dependent manner (Figure 4.5). 
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Figure 4.5: AUP1 overexpression reduced LPS-stimulated activation of NF-κB in 
KeratinoRI-/- cells 
7x104 KeratinoRI-/- cells/well were seeded in a 24-well plate and cultured overnight. Cells were 
cotransfected with the 3xNFκB-Luc plasmid and different amounts of a construct encoding FLAG-
hAUP1 as indicated. Total DNA concentration was kept constant at 12µg/2.5x106 cells by addition 
of empty vector. Transfected cells were either stimulated with 100 ng/ml LPS or were left untreated 
for control.  18 hours later, cells were lysed and luciferase activity was measured in cell lysates. 
Depicted is fold induction calculated by dividing relative light unit (RLU) values of stimulated 
samples by the RLU values of unstimulated controls. Data shown are triplicates of one 
representative experiment out of a series of three with comparable results. Lower panels: control of 
protein expression of FLAG-hAUP1 in cell lysates and GAPDH loading control.   
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4.6. AUP1 overexpression reduced IL-8 production of HEK293RI cells 
stimulated by IL-1β or TNFα 
Stimulation of cells with the pro-inflammatory cytokines IL-1β and TNFα results in 
the activation of transcription factors which translocate to the nucleus where they 
bind to specific promotors and turn on transcription of many genes. NF-κB is one of 
the most important transcription factors activated in inflammation. A large number 
of ligand-receptor interactions can lead to the activation of NF-κB. Two of the most 
frequently studied receptor families involved in the recognition of NF-κB-activating 
signals are the Tumor Necrosis Factor receptor (TNFR) family and the 
Toll/interleukin-1 receptor (TIR) family. Nuclear accumulation of NF-κB 
transcription factors causes changes in the expression of target genes involved in 
innate and adaptive immunity, inflammation, cell survival, hematopoiesis, and 
lymphoid development [Leeman, Gilmore –Gene – 2008] 
The results obtained in the NF-κB reporter gene assays performed in this study 
suggested that AUP1 overexpression impaired IL-1β, TNFα, and LPS signaling 
transduction. Thus, reduced NF-κB activation upon AUP1 overexpression should 
result in diminished secondary cytokine production. In order to confirm this, IL-1β- 
and TNFα-induced IL-8 production by HEK293RI overexpressing increasing 
amounts of AUP1 was examined.              
Overexpression of AUP1 diminished IL-1β and TNFα-induced IL-8 production by 
HEK293RI moderately in a dose-dependent manner (Figure 4.6).  
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The regulatory effect of AUP1 in IL-1β and TNFα-induced chemokine production 
was less pronounced than that observed in NF-κB -luciferase reporter gene assays 
(Figure 4.4). The possible explanation for this discrepancy is of a technical nature: 
In a reporter gene assay, the constructs encoding AUP1 and the NF-κB reporter 
gene are cotransfected so that cells which take up the NFκB-luciferase construct 
also internalize the AUP1 construct. Under stimulation, all cells induced to produce 
luciferase are also influenced by AUP1 overexpression. Thus, the background 
(untransfected cells) is excluded from the read-out, resulting in higher sensitivity of 
this method compared to the ELISA. In the chemokine production experiment, one 
hundred percent of cells are stimulated by the cytokine to produce the chemokine 
IL-8 but maximally 60-70% of the cell population overexpressed AUP1 due to the 
transfection efficiency. Thus, the background (unstransfected cells) is taken into the 
account and it reduces the sensitivity of this method. This results in a reduced 
difference between IL-8 production in control and in cells overexpressing AUP1.      
 
Figure 4.6: AUP1 overexpression diminished IL-8 production of HEK293RI stimulated with 
IL-1β and TNFα 
1x105 HEK293RI cells/well seeded and cultured overnight in a 24-well plate were transfected with 
increasing amounts of a construct encoding FLAG-hAUP1 as indicated. DNA concentration was 
kept constant at 6µg DNA/3.6x106 cells by addition of empty vector. On the next day, transfected 
cells were either stimulated with 100pg/ml rhIL-1β (A) or 10ng/ml rhTNFα (B) for 8 hours. 
Supernatant was harvested and hIL-8 in supernatant was measured by ELISA. Data shown are 
triplicates of one representative experiment out of a series of three with comparable results. 
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4.7. AUP1 overexpression diminished IL-6 production of KeratinoRI-/- 
cells stimulated with LPS 
As AUP1 overexpression reduced LPS stimulated NF-κB activation, it was 
investigated whether AUP1 overexpression also affected LPS-induced cytokine 
productions. Here IL-6 production by LPS-stimulated KeratinoRI-/- cells was 
investigated.  
Consistent with the results obtained with IL-1β and TNFα, overexpression of AUP1 
in KeratinoRI-/- reduced LPS-induced IL-6 production in a dose-dependent fashion 
(Figure 4.7)  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.8. AUP1 overexpression had no effect on the viability of HEK293RI and 
KeratinoRI-/- cells 
The ELISA approach showed that AUP1 overexpression reduced IL-8 and IL-6 
production in HEK293RI and KeratinoRI-/- cells stimulated with IL-1β, TNFα or 
LPS, respectively (Figure 4.6, 4.7). However, one can argue that the observed 
down-regulatory effect may be the result of enhanced cell death or reduced cellular 
proliferation due to the increase of AUP1 molecules after overexpression. To 
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Figure 4.7: AUP1 overexpression diminished IL-6 production of KeratinoRI-/- stimulated with 
LPS 
7x104 KeratinoRI-/- cells cultured overnight in wells of 24-well plate were transfected with 
increasing amounts of a construct encoding FLAG-hAUP1 as indicated. DNA concentration was 
kept constant at 12µg/2.5x106 cells by addition of empty vector. On the next day, transfected cells 
were stimulated with 100ng/ml LPS for 8 hours. Supernatant was harvested and mIL-6 was 
measured by ELISA. Data shown are triplicates of one representative experiment out of a series of 
three with comparable results.  
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exclude this posibility, MTT assay was performed to estimate the proliferation rate 
of HEK293RI and KeratinoRI-/- cells transfected with different amounts of a 
hAUP1 encoding construct. 
The results showed that overexpression of AUP1 in the ranges tested had no impact 
on cell viability and proliferation of HEK293RI and KeratinoRI-/- cells. This was 
not altered by either stimulation with IL-1β or LPS.    
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4.9. AUP1 overexpression impaired IL-1β and TNFα-induced activation 
of NF-κB but did not affect IL-6-induced activation of STAT3 in HepG2 
cells 
Reporter gene assays showed that overexpression of AUP1 resulted in the reduction 
of the activation of NF-κB in cells stimulated by IL-1β, LPS as well as TNFα 
(Figure 4.4, 4.5). One critical question arising from these results is the whether the 
observed effect of AUP1 is specific for these pro-inflammatory mediators or 
whether AUP1 generally affects a cellular function irrelevant of cytokine signaling. 
Figure 4.8: AUP1 overexpression did not affect the viabilty of HEK293RI (A) and 
KeratinoRI-/- (B) cells 
5x105 cells of HEK293RI or 3.5x105 cells of KeratinoRI-/- were plated to wells of 6-well plate and 
maintained in culture over night. Cells were then transfected with different concentrations of a 
plasmid encoding FLAG-hAUP1. DNA concentration was kept constant by addition of empty 
vector. Transfected cells were trypsinized and reseeded at density of 5x104 cells per well of 96-well 
plate. HEK293RI and KeratinoRI-/- cells were either stimulated with 100pg/ml rhIL-1β or 
100ng/ml LPS, respectively or were left unstimulated. 18 hours later, cell viability was determined 
by the MTT method. 
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Does overexpression of AUP1 globally affect the physiology of cells? To clarify 
this central question, the influence of AUP1 overexpression on the IL-6 signaling 
pathway was included in the study. IL-6 signaling is completely different from IL-1, 
LPS and TNFα pathways. IL-6 cytokine exerts its action via the IL-6 receptor and 
the signal transducer gp130 leading to the activation of the JAK/STAT (Janus 
kinase/ signal transducer and activator of transcription) and the MAPK (mitogen-
activated protein kinase) cascades [Heinrich et.al. – Biochemical Journal – 2003].  
It was reported that HEK293 cells express IL-6 receptor, gp130 and respond to IL-6 
stimulation [von Laue et. al. – The journal of endocrinology – 2000]. In addition, 
HEK293 were used to demonstrate the function of AUP1 in IL-1β and TNFα 
pathway in the present study. Therefore, HEK293 appeared to be the ideal cell line 
to investigate the function of AUP1 in the IL-6 signaling pathway. 
First, the response of HEK293RI to IL-6 stimulation was tested by the 
phosphorylation of STAT3, the major member of STAT family activated by IL-6 
[Heinrich et.al. – Biochemical Journal – 2003]. STAT3 is primarily phosphorylated 
at Tyr705 residue, and it also requires phosphorylation at Ser727 to achieve 
maximal activity [Wen et.al. – Cell – 1995; Zhang et.al. – Science – 1995]. 
HEK293RI cells were either stimulated with rhIL-6 for 15, 30 minutes or left 
unstimulated for control and the phosphorylation of STAT3 at Tyr705 and Ser727 
residues were detected with Western blot using phosphorylation site –specific 
antibodies. In parallel, human hepatocellular carcinoma HepG2 cells which respond 
well to IL-6 were used in this experiment as positive control.  
In HepG2 STAT3 was phosphorylated strongly at Tyr705 residue after 15 minutes 
of IL-6 stimulation. The phosphorylation at Ser727 residue also occurred. Although 
the background in the sample from unstimulated cell was rather high, the induced 
phosphorylation at Ser727 of STAT3 was obvious (Figure 4.9). In contrast to 
HepG2 cell, in HEK293RI no phosphorylation of STAT3 at Tyr705 residue could 
be detected after stimulation of IL-6 for 15 or 30 minutes. In the case of 
phosphorylation of STAT3 at Ser727, it was undistinguishable between IL-6 
stimulation and unstimulation (Figure 4.9). Moreover, IL-8 release into culture 
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supernatant of HEK293RI stimulated with IL-6 could not by measured by ELISA 
(data not shown). Thus, in contrast to results from literature, HEK293RI of this 
laboratory did not seem to react to IL-6 and thus could not be used to test the 
function of AUP1 with respect to IL-6 responsiveness.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For studying possible AUP1 effects on IL-6 signaling HepG2 cells were used. 
HepG2 cells were transiently transfected with increasing amounts of hAUP1 
encoding construct together with pGL3- 2M-215Luc construct which contains a 
STAT3-dependent promoter fused to the luciferase encoding sequence (a kind gift 
of F. Schaper, RWTH, Aachen, Germany [Schaper et.al. – Biochemical Journal – 
1998; Schmitz et.al. – JBC – 2000; Lehmann et.al. – JBC – 2003]). The influence of 
AUP1 overexpression on the IL-6 pathway was measured using luciferase reporter 
gene assay. To compare the role of AUP1 overexpression in IL-1, TNFα pathway 
and IL-6 pathway in the same cell line, IL-1β- and TNFα-induced NF-κB activation 
were also demonstrated in HepG2 overexpressed AUP1. 
Overexpression of AUP1 in HepG2 did not alter IL-6-induced activation of STAT3 
(Figure 4.10). This result suggested that AUP1 overexpression may not be involved 
in the IL-6 signaling pathway, demonstrating a relative specificity of AUP1 
overexpression on selected signaling pathways. Similarly to the results obtained in 
HEK292RI cells, overexpression of AUP1 reduced IL-1β- and TNFα-stimulated 
activation of NF-κB in a dose-dependent fashion in HepG2 cells (Figure 4.10). 
These results manifested that AUP1 is involved in some signaling pathways 
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HepG2 HEK293-RI Figure 4.9: HEK293RI cells do 
not respond to IL-6 stimulation 
by STAT3 phosphorylation 
HEK293RI and HepG2 cells were 
starved in DMEM medium with 
0.1%FCS overnight. Cells were 
stimulated with 20ng/ml rhIL-6 for 
the times indicated. Cells were 
then lysed, lysates were subjected 
to SDS-PAGE and Western blot 
using antibodies against phospho-
STAT3 (Tyr705), phospho-STAT3 
(Ser727) and total STAT3. 
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physiology of cells. 
 
     
 
 
 
 
 
            
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.10. AUP1 associates with TNFR-1, TRADD, and TRAF2 
The results given by reporter gene assay (Figure 4.4, 4.10) and ELISA for IL-8 
production (Figure 4.6B) suggest that AUP1 may be involved in the TNFα signaling 
pathway. As AUP1 binds to proteins involved in the IL-1 signaling pathway, it is 
also possible that AUP1 interacts with components of the TNFα pathway. 
To confirm this, the interaction of AUP1 and TNFR1, TRADD and TRAF2 - three 
molecules of the TNFα-induced survival pathway (see part 1.7) – were investigated 
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Figure 4.10: AUP1 overexpression impaired IL-1β- and TNFα-induced activation of NF-κB 
but did not affect IL-6-induced activation of STAT3 in HepG2 cells 
5.5x104 HepG2 cells/well were cultured in a 24-well plate overnight. Cells were cotransfected with 
constructs encoding either a 3xNFκB-Luc reporter gene (for IL-1β and TNFα stimulation) or a 
pGL3-α2M-215Luc reporter gene (for IL-6 stimulation) and increasing amounts of FLAG-hAUP1
encoding construct as indicated. DNA concentration was kept constant at 6µg/2x106 cells by 
addition of empty vector. Transfected cells were either stimulated with 1ng/ml rhIL-1β, 10ng/ml 
rhTNFα, 20ng/ml rhIL-6 or were left untreated. Cells were lysed and luciferase activity in cell 
lysates was measured the next day. Depicted is fold induction calculated by dividing relative light 
unit (RLU) values of stimulated samples by the RLU values of unstimulated controls. Data shown 
are triplicates of one representative experiment out of a series of three with comparable results. 
Lower panels: protein expression of FLAG-hAUP1 in cell lysates and GAPDH for loading control.  
Protein expression 
NF-κB reporter 
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using co-IP experiments. As depicted in Figure 4.11, the association experiment 
provided evidence that AUP1 interacts with TNFR1, TRADD and TRAF2 at least in 
the overexpression situation. AUP1 was found to associate with all of three tested 
molecules but with different intensity. AUP1 associated stronger with TNFR1 than 
with TRAF2 or TRADD (Figure 4.11 - upper panel), although the expression level 
of Myc-TNFR1 in cells was extremely low compared to Myc-TRADD and Myc-
TRAF2 (Figure 4.11 - lower panel). Hence, the possibility that TRADD and TRAF2 
associate with AUP1 indirectly through endogenous TNFR1 can not be excluded. 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: AUP1 associates with components of the TNFα signaling pathway 
HEK293RI cells were cotransfected with plasmids encoding Myc-hTNFR1, Myc-hTRADD, Myc-
hTRAF2 and either FLAG-hAUP or empty vector for unspecific binding control. In parallel, Myc-
hAUP1 construct was cotransfected with either FLAG-hIL-1RI or empty vector for control to 
HEK293RI. On the next day, cells were lysed and cell lysates were incubated with anti-FLAG M2 
beads. Co-immunoprecipitated proteins were analysed by Western blot using anti Myc-epitope 
antibody and then membrane was stripped and reprobed with anti FLAG-epitope antibody. For 
overexpression control, cell lysates were separated by SDS-PAGE followed by Western blot using 
anti Myc-epitope antibody. Data shown is one representative experiment out of a series of three with 
comparable results.             
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4.11. AUP1 interacts with the IL-6R α-chain (gp80) but not with gp130  
In Figure 4.10 it was shown that AUP1 overexpression impairs both the IL-1β and 
TNFα signaling pathways, but does not interfere with IL-6 signaling in HepG2 
cells. And AUP1 interacted with both the IL-1RI complex (Figure 4.1, 4.2) and the 
TNFR1 complex (Figure 4.11). As AUP1 overexpression did not affect IL-6 
signaling, it was investigated whetherAUP1 interacts with IL-6R (gp80) and gp130, 
the two components of the IL-6 receptor complex. In the IL-6 signaling pathway, 
IL-6 binds specifically to both receptor subunits, the IL-6 receptor α-chain and 
gp130, with distinct residues. However, the signal is only transduced by gp130 as 
soluble IL-6 receptor α-chains in combination with gp130 can initiate IL-6 signaling 
in cells lacking transmembrane IL-6 receptor α-chains by trans-signaling [Rose-
John, Schooltink – Recent Results Cancer Res – 2007]. gp130 which associates with 
JAKs and becomes tyrosine phosphorylated in response to cytokine stimulation 
plays the central role in IL-6 signaling transduction [Heinrich et.al. – Biochemical – 
2003].        
To investigate the association between AUP1 and the IL-6R components, plasmids 
encoding the candidate proteins were transiently transfected to HEK293RI. 
Subsequently, co-IP was carried out followed with Western blot analysis. 
This association experiment demonstrated that AUP1 interacted with the non-
signaling IL-6R α-chain (Figure 4.12-A) but not with the signal transducing 
receptor subunit gp130 (Figure 4.12-B). Although AUP1 overexpression did not 
influence IL-6 signaling transduction with respect to STAT3 activation (Figure 
4.10), the involvement of AUP1 in IL-6 pathway can not be excluded because of the 
interaction between AUP1 and IL-6R. 
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4.12. Effect of small-interfering RNA (siRNA)–mediated knockdown of 
hAUP1 in HEK293RI and HepG2 cells 
As stated in the introduction to the results section, in order to study biological 
function of AUP1 removing the protein from cells is as important as overexpressing 
it. Therefore, silencing of AUP1 expression in HEK293RI and HepG2 cell lines was 
performed with small-interfering RNA (siRNA) using ON-TARGETplus 
SMARTpool siRNA for hAUP1 (L-012410-01-0005 – Dharmacon RNAi 
Technologies – Thermo scientific). Anti hAUP1 siRNA pool consisted of four 
commercially obtained siRNAs for target sequences (detailed information in 
materials section). A scrambled siRNA was included as control for the effect of 
transient transfection of small RNAs in cells. Transfection with siRNA was carried 
out according to manufacturer’s instruction with a slight optimization as described 
IL6R-HA          +     + 
Flag-AUP1       +      - 
72 
72 
95 
43 
IP: anti FLAG 
WB: anti HA 
IP: anti FLAG 
WB: anti FLAG 
Lysates 
WB: anti HA
gp130-Flag      +    -     - 
Flag-IL1RI      -     -     + 
Myc-AUP1      +    +    + 
43
72
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43
IP: anti FLAG 
WB: anti Myc 
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WB: anti FLAG 
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Figure 4.12: AUP1 interacts with the non-signaling receptor IL-6Rα chain (A) but not with 
the signal transducing subunit gp130 (B) 
(A) HEK293RI cells were cotransfected with constructs encoding hIL6R-HA and either FLAG-
hAUP1 or empty vector for unspecific binding control. On the next day, cells were lysed and cell 
lysates were incubated with anti-FLAG M2 beads. Co-immunoprecipitated proteins were analysed 
by Western blot using anti HA-epitope antibody and then membrane was stripped and reprobed 
with anti FLAG-epitope antibody. The expression of IL6R-HA in lysates was confirmed by SDS-
PAGE followed by Western blot using anti HA-epitope antibody.   
(B) HEK293RI cells were cotransfected with plasmids encoding Myc-hAUP1 and either hgp130-
FLAG or FLAG-hIL1RI or empty vector for unspecific binding control. On the next day, cells were 
lysed and cell lysates were incubated with anti-FLAG M2 beads. Co-immunoprecipitated proteins 
were analysed by Western blot using anti Myc-epitope antibody and then membrane was stripped 
and reprobed with anti FLAG-epitope antibody.  The expression of Myc-AUP1 in lysates was 
confirmed with SDS-PAGE followed by Western blot using anti Myc-epitope antibody.   
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in part 2.2.13 and legend of Figure 4.13. The AUP1 knock-down efficiency was 
monitored at mRNA and protein level with RT-qPCR and Western blot.  
RT-pPCR experiment showed that siRNA-mediated knock-down efficiency of 
AUP1 mRNA in HEK293RI and HepG2 reached more than 80% and 70%, 
respectively. Consistent with the results on mRNA level, AUP1 protein expression 
in HEK293RI and HepG2 anti-AUP1 siRNA transfectants was reduced significantly 
as demonstrated by Western blot analysis (Figure 4.13).   
 
A                                                                         B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Small-interfering RNA (siRNA)–mediated knockdown of hAUP1 in HEK293RI 
(A) and HepG2 (B) cells 
24h before transfection, 6x104 cells of HEK293RI or HepG2 /well were seeded in a 24-well plate. 
Cells were either transfected with 100nM of anti-hAUP1 siRNA, scramble siRNA or treated with 
transfection reagent only for mock control. 24 hours post-transfection, total RNA from cells was 
isolated and RT-qPCR was performed to compare quantity of AUP1 mRNA in cells. For AUP1 
protein examination, 48 hours post-transfection, cells were lysed and lysates were analysed by SDS-
PAGE and Western blot using anti-AUP1 antibody. Membranes were stripped and reprobed with 
anti-GAPDH antibody for loading control. Data shown is one representative experiment out of a 
series of three with comparable results.                
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4.13. Silencing of AUP1 increased IL-1β- and TNFα-induced                  
IL-8 production and activation of NF-κB in HEK293RI cells as well as 
IL-6-induced activation of STAT3 in HepG2 cells 
Overexpression experiments suggested that AUP1 exhibits a partially inhibitory 
activity in IL-1β, TNFα, LPS signaling pathways (Figure 4.4 – 4.7). To confirm this 
finding, the influence of siRNA-mediated AUP1 silencing on IL-1β- and TNFα-
induced signaling transduction in HEK293RI cells was investigated. Cytokine 
release in form of IL-8 production and activation of transcription factors in form of 
NF-κB-luciferase reporter gene assay were measured. In addition, IL-6-induced 
activation of STAT3 was also examined with reporter gene assay in HepG2 cells in 
which AUP1 expression had been silenced by use of siRNA.. 
IL-1β- and TNFα -induced IL-8 production was enhanced in anti-hAUP1 siRNA 
transfected HEK293RI cells compared to that in control cells receiving scrambled 
siRNA (Figure 4.14-A). Consistent with this observation, IL-1β and TNFα 
stimulated NF-κB activation in AUP1 knock-downed cells was higher than in 
control cells as shown in NF-κB-luciferase reporter gene experiment (Figure 4.14-
B). These results, together with previous data in overexpression experiments, 
provided evidence that AUP1 is a negative regulator of signaling transduction 
induced by IL-1 (LPS) and TNFα. Silencing of AUP1 in HepG2 resulted in an 
increase of STAT3 activation upon IL-6 stimulation compared to that in control 
cells (Figure 4.14-C).  
Taken together, AUP1 seems to be a common negative regulator of IL-1β/LPS, 
TNFα and IL-6 signaling pathways. Moreover, the siRNA-mediated silencing of 
AUP1 also induced constitutive IL-8 production, and NF-κB as well as STAT3 
activation independently of cytokine stimulation (Figure 4.14).  
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Figure 4.14: Silencing of AUP1 increased IL-1β-, TNFα-induced IL-8 production (A) and 
activation of NF-κB in HEK293RI cells (B) as well as IL-6-induced activation of STAT3 in
HepG2 cells (C)  
(A) 48h after transfected with 100nM of anti-hAUP1 siRNA or scramble siRNA, HEK293RI cells 
were stimulated with either rhIL-1β (100pg/ml) or rhTNFα (10ng/ml) for 8 hours. Supernatant was 
harvested and hIL-8 in supernatant was quantified with ELISA.  
(B) 44h after transfected with 100nM of anti-hAUP1 siRNA or scramble siRNA, HEK293-RI cells 
were transfected with 3xNFkB-Luc reporter gene construct. Transfected cells were either stimulated 
with rhIL-1β (100pg/ml), rhTNFα (10ng/ml) for 8 hours or were left untreated for control. Cells 
were lysed and luciferase activity in cell lysates was measured. RLU was normalized with protein 
concentration of lysates. 
(C) 44h after transfected with 100nM of anti-hAUP1 siRNA or scramble siRNA, HepG2 cells were 
transfected with pGL3-α2M-215Luc reporter gene construct. Transfected cells were either 
stimulated with rhIL-6 (20ng/ml) for 8 hours or were left untreated for control. Cells were lysed and 
luciferase activity in cell lysates was measured. RLU was normalized with protein concentration of 
lysates.              
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4.14. AUP1 overexpression reduced IL-1β-induced phosphorylation of 
JNK, p38 MAPK and delayed the degradation of IκB in HEK293RI cells 
It was reported previously that AUP1 is evolutionarily conserved and ubiquitously 
expressed, hence it appears to play basic and essential roles in cellular biology [Jang 
et.al. – Genomics – 1996; Kato et.al. – JBC – 2002]. The data obtained in this study 
propose that AUP1 is likely a common negative regulator of many signaling 
pathways. However, it is important to confirm the role of AUP1 to suppress 
signaling transduction rather than to regulate basic events such as protein synthesis 
which can result in the reduction of luciferase enzyme and cytokine production as 
seen in above experiments.  
Therefore, the kinetics of some important events in IL-1β-mediated signaling 
including phosphorylation and degradation of IκB, phosphorylation of JNK, 
phosphorylation of p38 were investigated in the presence and absence of AUP1 
overexpression.     
In HEK293RI, AUP1 overexpression did not shift the IL-1β-induced kinetic of JNK 
phosphorylation compared to those in empty vector control. JNK phosphorylation 
reached the peak at 30 minute of IL-1β exposure and then decreased. However, in 
cells overexpressing AUP1, the intensity of phosphorylation of JNK was reduced 
compared to control (Figure 4.15- phospho JNK). A similar phenomenon occurred 
with p38 phosphorylation. In the presence of AUP1 overexpression, IL-1β-induced 
phosphorylation of p38 was decreased significantly compared to that of empty 
vector control. As with JNK, the kinetic of p38 phosphorylation was not altered by 
overexpression of AUP1. The phosphorylation of p38 reached the peak after 30 
minutes stimulation with IL-1β in both cases with and without AUP1 
overexpression (Figure 4.15- phospho p38). IκB is the inhibitor of NF-κB, the 
phosphorylation and the degradation of IκB is essential for the activation of NF-κB. 
In cells overexpressing AUP1, the IL-1β-induced degradation of IκB was not 
reduced but delayed compared to those in control cells. IκB was degraded rapidly 
after 5 minute stimulation of IL-1β in control cells while it was slower in AUP1 
expressing cells. However, after longer stimulation (15 minute), IκB degradation 
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was the same in cells with and without AUP1 overexpression (total IκB - Figure 
4.15).  
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Figure 4.15: AUP1 overexpression reduced IL-1β-induced phosphorylation of JNK, p38 
MAPK and delayed degradation of IκB in HEK293RI 
HEK293RI cells were transfected either with FLAG-hAUP1 encoding plasmid (6µg/3,6x106 cells) 
or empty vector. On the next day, transfected cells were stimulated by 5ng/ml rhIL-1β for the 
indicated times. Cells were lysed, lysates were subjected to SDS-PAGE and Western blot using 
antibodies against phospho-JNK, total-JNK, phospho-p38, total-p38, phospho-IκB, total IκB. The 
expression of FLAG-hAUP1 was confirmed with Western blot using anti FLAG antibody and anti 
GAPDH antibody was used for loading control. Data shown is one representative experiment out of 
a series of three with comparable results.  
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4.15. AUP1 overexpression reduced the degradation of IκB and delayed 
the phosphorylation of p38 MAPK also in KeratinoRI-/- cells stimulated 
with LPS 
With the same purpose as discussed in part 4.14, the kinetics of LPS-mediated 
phosphorylation and degradation of IκB, phosphorylation of JNK, phosphorylation 
of p38 were investigated in the presence and absence of AUP1 overexpression.               
In KeratinoRI-/- cells, AUP1 overexpression did not shift the LPS-induced kinetic 
of IκB degradation compared to those of empty vector control. In both cases, IκB 
was degraded the most at 60 minute of LPS stimulation and then new IκB was 
synthesized in feedback mechanism of the signaling pathway. Nevertheless, in 
AUP1 overexpressed cells, the LPS-mediated degradation of IκB was reduced, 
especially at time points 30min and 60min, compared to those of control cells 
(Figure 4.16- total IκB). In contrast, there was no difference in LPS-induced 
phosphorylation of IκB between AUP1 transfectant and empty vector transfectant 
(Figure 4.16- phospho-IκB). The remaining phospho-IκB was the result of the 
balance between two simultaneous processes phosphorylation and degradation. 
Thus, it is unable to comment upon the relation between LPS-induced 
phosphorylation of IκB and AUP1 overexpression. In the presence of AUP1 
overexpression, LPS-induced phosphorylation of p38 was delayed compared to 
those of empty vector control. In control cells, the peak of p38 phosphorylation was 
achieved at 120min after LPS stimulation while in AUP1 overexpressed cells, it 
occurred at 180min (Figure 4.16- phospho-p38). However, the phosphorylation of 
JNK was not modified by the overexpression of AUP1 in KeratinoRI-/- cells 
stimulated with LPS (Figure 4.16- phopho-JNK). 
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The results shown in Figure 4.15 and 4.16 indicated that AUP1 overexpression 
impairs IL-1β- and LPS-mediated signaling pathways. AUP1 perhaps interferes with 
IL-1 and LPS signaling pathways at the level of the activator of IκB: the NEMO-
IKK complex and at the activator of the JNK - p38 MAPK: the MKKs or upstream 
of them.  
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Figure 4.16: AUP1 overexpression reduced the degradation of IκB and delayed the 
phosphorylation of p38 MAPK in KeratinoRI-/- stimulated with LPS 
KeratinoRI-/- cells were transfected either with FLAG-hAUP1 encoding plasmid (12µg/2,5x106
cells) or empty vector. On the next day, transfected cells were stimulated by 1µg/ml LPS for the 
indicated times. Cells were lysed, lysates were subjected to SDS-PAGE and Western blot using 
antibodies against phospho-IκB, total-IκB, phospho-JNK, total-JNK, phospho-p38, total-p38. The 
expression of FLAG-hAUP1 was confirmed with Western blot using anti FLAG antibody and anti 
GAPDH antibody was used for loading control. Data shown is one representative experiment out of 
a series of four with comparable results.  
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4.16. AUP1 overexpression reduced IL-1β- and LPS-induced DNA-
binding activity of NF-κB-p65 in HEK293RI and KeratinoRI-/- cells 
In order to provide more evidence for the direct interference of AUP1 
overexpression with signaling pathways, the IL-1β- and LPS-mediated DNA-
binding activation of NF-κB-p65 subunit were determined in the presence or 
absence of AUP1 overexpression.  
Once IL-1β or LPS engage to their receptors, they initiate signaling cascades with 
many events through many mediate proteins. An important outcome of this 
complicated process is the phosphorylation and degradation of NF-κB inhibitor IκB 
resulting in the translocation of NF-κB to nucleus [Michael U.Martin, Holge 
Wesche – BBA – 2002; Foo Y.Liew et. al. – Nature –  2005]. NF-κB mainly exists 
the heterodimer consisting of p65 (RelA) and p50 in cells. In the nucleus, activated 
NF-κB p65-p50 binds to promoters and stimulates transcription of genes containing 
consensus sequence κB 5’-GGGPuNNPyPyCC-3’ (Pu: purines, Py: pirimidines) 
[Okamoto et. al. – Current Pharmaceutical Design – 2007].  
IL-1β- and LPS-activated NF-κB-p65 in nuclear extracts of HEK293RI and 
KeratinoRI-/- cells with or without overexpression of AUP1 were measured using 
Panomics’TF ELISA kit according to the manufacturer’s instruction.  
In HEK293RI cells transfected with the empty vector, the DNA-binding activity of 
NF-κB-p65 increased significantly following the time course of IL-1β stimulation 
(Figure 4.17A-black square line). However, in AUP1 overexpression, the kinetic of 
IL-1β-induced DNA-binding activity of NF-κB-p65 was reduced (Figure 4.17A-
white round line) compared to the control. In KeratinoRI-/- cells, AUP1 
overexpression also impaired LPS-induced DNA-binding activity of NF-κB-p65 
compared to the empty vector control (Figure 4.17B). These results support for the 
regulatory function of AUP1 in IL-1β and LPS pathways.   
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Figure 4.17: AUP1 overexpression reduced IL-1β- and LPS-induced DNA-binding activity of 
NF-κB-p65 in HEK293RI and KeratinoRI-/- cells  
HEK293RI (A) and KeratinoRI-/- (B) cells transfected with FLAG-hAUP1 encoding construct were 
stimulated with  5ng/ml rhIL-1β and 1µg/ml LPS, respectively, for the indicated times. Empty 
vector transfectants were used as control. After stimulation, cells were lysed and nuclear lysates 
were isolated. Activated NF-κB-p65 in nuclear lysates was determined by binding activity to κB-
consensus sequence DNA probe using Panomics’TF ELISA kit as manufacturer’s instruction. 
Depicted are OD450nm values which reflect relative amount of activated NF-κB-p65.  
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5. DISCUSSION 
IRAK4 plays a critical role in TLR/IL-1R signaling pathways. Upon challenges of 
TLR ligands, IRAK4 deficient mice exhibited severe impairment of NF-κB 
activation and cytokine production [Suzuki et. al. – Nature – 2002]. The kinase 
activity of IRAK4 was proved necessary for IL-1/LPS-induced NF-κB activation 
[Li et. al. – PNAS – 2002]. Recently, a study in IRAK4 kinase inactive knock-in 
cells showed that IRAK4 kinase activity is required for TLR-mediated JNK and p38 
signaling but not for NF-κB and IRF3 activation [Koziczak-Holbro et. al. – Eur J 
Immunol – 2008]. IRAK4 was proposed to be involved critically in TCR (T cell 
receptor) – induced T cell proliferation through NF-κB activation. IRAK4, 
therefore, may be a connection between innate and adaptive immunity [Suzuki et. 
al. – Science – 2006]. In addition, IRAK4 can phosphorylate NADPH oxidase 
cytosolic factor p47phox in neutrophils at Thr133 and Thr356 locating in the consensus 
sequence (D/E)XQTX(K/R) which is similar to the consensus sequence in the 
kinase activation loop (QT383VR) of IRAK1, the well-known subtrate of IRAK4 
[Pacquelet – Biochemical Journal – 2007]. This observation implicates that IRAK4 
may phosphorylate structurally related proteins with different roles in distinct 
cellular events. These diversified data on IRAK4 suggest that more not yet defined 
functions of IRAK4 may exist. Thus, seeking new partners of IRAK4 is helpful to 
elucidate the signaling network of IRAK4.          
The yeast two-hybrid screening was performed to define partners of IRAK4 from 
proteins encoded by a cDNA library derived from human placenta tissue (C.Linke 
& M.U.Martin unpublished). Analysis of screening results revealed novel partner 
proteins of IRAK4 AUP1 (ancient ubiquitous protein 1) being one of them 
(C.Kollewe & M.U.Martin unpublished). 
AUP1, identified and cloned in 1996, is a protein which is highly conserved in 
evoultion. The sequence similarity of mouse AUP1 protein with the Caenorhabditis 
elegans or human counterpart molecules is 53% or 90%, respectively. This degree 
of evolutionary conservation is comparable to that of essential proteins such as 
pyruvate kinase and ribosomal protein L3. In addition, AUP1 is expressed in nearly 
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all tissues of mouse and human [Jang et.al. – Genomics – 1996; Kato et.al. – JBC – 
2002]. Therefore, it is highly likely that AUP1 plays a basic and essential role in the 
biology of cell. However, although the molecule is known for some years now, the 
biological functions of AUP1 are still obscure. AUP1 was proposed to associate 
with the cytoplasmic tail of the αIIb subunit of the integrin receptor and with Syk 
protein which binds to the β3 subunit in megakaryocyte-derived UT7/TPO cells. By 
this way, AUP1 links the cytoplasmic tails of αIIb and β3 subunits and sustains the 
αIIbβ3 complex in an inactive state [Kato et.al. – JBC – 2002; Kato, Oshimi – 
Platelets – 2009]. On the other hand, AUP1 was reported to be involved in the 
dislocation and degradation of glycoproteins in endoplasmic reticulum [Mueller et. 
al. – PNAS – 2008].  To date, no information is available on the participation of 
AUP1 in cytokine signaling. 
 
5.1. AUP1 interacts with IRAK4 and IRAK1 in mammalian cells 
It is well known that the search for protein interaction with the yeast two-hybrid 
system is proned to yield false positive results. Therefore, it was necessary to 
demonstrate the interaction between AUP1 and IRAK4 found in the yeast two-
hybrid screening also in mammalian cells. The interaction of AUP1 with IRAK4 
was confirmed in HEK293RI cells. If both candidate proteins were overexpressed 
they could be co-immunprecipitated. As IRAK4 is only one out of four members of 
serine-threonine protein kinases found to be involved in IL-1 signaling, IRAK1 was 
also examined for the interaction with AUP1. Interestingly, AUP1 was found to 
associate with IRAK4 and IRAK1 molecules, but only if kinase inactive mutants 
were employed for co-immunoprecipitation experiments. The interaction of AUP1 
with wild type IRAK4 and IRAK1 which are both kinase active, could not be 
detected in co-immunoprecipitation experiments suggesting that it was very 
transient and dependent on the phosphorylation state of IRAK molecules. The 
phosphorylation state of IRAK4 and IRAK1 strongly influence the interaction with 
other partners. Phosphorylated IRAK4 and IRAK1 dissociate from the adapter 
protein MyD88 [Wesche et. al. – Immunity – 1997; Gottipati et. al. – Cellular 
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Signalling – 2008]. It was previously shown that, under overexpression conditions 
wild type IRAK4 and IRAK1 become constitutively active and then auto-
phosphorylate independent of cytokine stimulation of cells [Li et. al. – PNAS – 
2002; Neumann et. al. – Journal of Leukocyte Biology – 2008]. Obviously, kinase 
inactive IRAK4 and IRAK1 mutants are unable to phosphorylate themselves in an 
overexpression situation and thus the interaction with AUP1 was sustained as shown 
in the co-immunoprecipitation studies. Taken together, it is possible that the 
phosphorylation of IRAK4 and IRAK1 interferes with their interaction with AUP1. 
This observation is similar to one made with Tollip, a molecule that was described 
to be a silencer for IRAK1. This molecule can be detected in complex with kinase 
inactive IRAK1 but not with the wild type molecule due to its sensitivity to 
phosphates introduced in IRAK1 after activation of its kinase activity [Burns et.al. – 
Nature – 2000]. Besides of auto-phosphorylation, active IRAK4 and IRAK1 
phosphorylate other proteins such as Tollip and Pellino2 [Zhang, Ghosh – JBC – 
2002; Strelow et. al. – FEBS Lett – 2003].  
 
5.2. AUP1 is phosphorylated by IRAK4 and possibly IRAK1 
Therefore, it was necessary to investigate whether AUP1 is a substrate for IRAK4 
and IRAK1. Since wild type IRAK4 and IRAK1 do not interact with AUP1 or the 
transient interaction is so short lived that it could not be detected in co-
immunoprecipitation experiments, forced co-immunoprecipitation assays were 
performed followed by in vitro kinase assays. This experimental approach was 
originally developed to force together two molecules which normally would only 
interact briefly. Both molecules, kinase and putative substrate are expressed with the 
same epitope tag and an antibody is used to immunoprecipitate the two together. 
Statistically kinase and substrate will be forced into close proximity by the bivalent 
antibody. If this was performed on a bead, an in vitro kinase assay can easily be 
perfomed in the presence of radioactive ATP. The results obtained with such 
experiments showed that AUP1 can be phosphorylated by IRAK4. A much weaker 
signal was also observed with IRAK1, suggesting that AUP1 was also a substrate 
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for IRAK1 under these conditions. However, one has to keep in mind that the 
overepxression was done in HEK293RI cells possessing endogenous IRAK4 and 
IRAK1. As all IRAK family members readily form heterodimers due to their death 
domains which are excellent homotypic protein interaction domains, it cannot be 
excluded that together with overexpressed IRAK1 carrying the tag necessary for 
forced co-immunoprecipitation endogenous IRAK4 molecules were unwantingly 
co-precipitated. These molecules would be activated by overexpressed IRAK1 and 
could then phosphorylate AUP1 on the bead. Thus, at present it cannot be excluded 
that in fact only IRAK4 accepts AUP1 as substrate. This observation may indicate 
the involvement of AUP1 in the TLR/IL-1R signaling pathways. However, it was 
proposed that members of the IRAK family phosphorylate structurally related 
proteins which play roles in very distinct cellular events [Pacquelet – Biochemical 
Journal – 2007]. A database search for the homologous domain structure revealed 
that hAUP1 contains 5 phosphorylation sites for Protein kinase C, 5 phosphorylation 
sites for Casein kinase II and 1 phosphorylation site for cAMP- and cGMP- 
dependent protein kinases which are all serine/threonine kinases 
[http://us.expasy.org/tools/scanprosite/]. Thus, AUP1 is likely susceptive to be 
phosphorylated by serine/threonine kinases in general. Thus, the phosphorylation of 
AUP1 in forced close proximity to IRAK4 may be an in vitro situation which would 
need proof in vivo.         
 
5.3. AUP1 interacts with many, but not all components in IL-1 signaling 
complex 
In order to ascertain the involvement of AUP1 in the IL-1 signaling pathway, the 
interaction of AUP1 with several functional components of the IL-1 signaling 
transduction machinery was investigated including upstream molecules such as IL-
1RI, MyD88 and Tollip and downstream components such as TRAF6 and Pellino2. 
The co-immunoprecipitation results revealed that AUP1 associates constitutively 
with quiescent IL-1RI and dissociates partially from the receptor complex after a 
brief IL-1β stimulation. AUP1 also associated with other components of the IL-1RI 
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complex such as IL-1RAcP (data not shown), MyD88, Tollip, and especially with 
TRAF6 – the direct downstream signaling transducer of IRAK1. As reported 
previously, the overexpression of TRAF6 is sufficient to activate downstream 
events toward activation of NF-κB [Frobose et. al. – Molecular Endocrinology – 
2006]. Auto-ubiquitination of TRAF6, an E3 ubiquitin ligase, is critical for the IL-1-
dependent signaling pathway [Cao et. al. – Nature – 1996; Lamothe et. al. – JBC – 
2007]. The ubiquitination of TRAF6 is essential for the direct interaction of TRAF6 
with TAK1-TAB1-TAB2/TAB3 complex via TAB2/TAB3. TAB2/TAB3 binds to 
the K63-polyubiquitin chain of TRAF6 and by that way links TRAF6 to TAK1 
[Tekaesu et. al. – Mol Cell – 2000; Ishitani et. al. – EMBO – 2003]. In addition, 
TAB2 was reported to facilitate TRAF6 ubiquitination and thereby to mediate IL-1-
induced cellular events. The N-terminal region of TAB2 contains an ubiquitin 
binding domain, the CUE domain, which is important for TAB2-dependent 
activation of NF-κB. However, the CUE domain is dispensable for the TRAF6 
binding of TAB2 [Kishida et.al. – Genes to Cells – 2005]. AUP1 also possesses a 
CUE domain and it associates strongly with TRAF6, thus AUP1 may play an active 
role in the TRAF6 function.  
As AUP1 interacted with so many molecules in IL-1 signaling it was necessary to 
question its selectivity. In that respect it is interesting to note that AUP1 does not 
interact with all molecules known to participate in IL-1 signaling, thus no 
interaction was observed e.g. with Pellino2.                
 
5.4. Overexpression of AUP1 impairs the IL-1 and LPS signaling 
transductions but the regulatory effect is not specific for these pathways 
All the above findings suggested that AUP1 may play a regulatory role in the IL-1 
signaling pathway. In order to elucidate the biological function of AUP1 in IL-1-
mediated signaling, the influence of AUP1 overexpression on IL-1β- and LPS-
induced signaling transduction was investigated in HEK293RI and KeratinoRI-/- 
cells, respectively. Cells transfected with different amounts of a hAUP1 encoding 
plasmid were stimulated by IL-1β or LPS and signaling transduction was measured 
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by NF-κB -dependent firefly luciferase expression, IL-8, and IL-6 production. 
Results suggested that AUP1 overexpression partially inhibited IL-1β and LPS-
induced signaling pathways in a dose-dependent manner.  
The overexpression of AUP1 in the ranges tested had no impact on viability and 
proliferation of transfected HEK293RI and KeratinoRI-/- cells as shown in MTT 
assays.  
Because of AUP1’s evolutionary conservation and ubiquitous expression [Jang et.al. 
– Genomics – 1996; Kato et.al. – JBC – 2002], it was necessary to verify whether 
the observed regulatory effect of AUP1 overexpression was specific for IL-1β and 
LPS signaling. TNFα is a pro-inflammatory cytokine with a biological effector 
profile overlapping that of IL-1. However, TNF utilizes a discrete receptor system 
and related but distinct adaptor molecules to activate NF-κB inducing kinase and 
finally IκB kinases. Thus, TNFα and IL-1 signaling converge at the activation of 
NF-κB. Therefore, TNFα-activated signaling transduction was investigated in 
HEK293RI cells overexpressing increasing amounts of hAUP1 by NF-κB -
dependent firefly luciferase expression and IL-8 production. Similarly to the results 
obtained after IL-1β and LPS stimulation, overexpression of AUP1 in HEK293RI 
cells was also impaired significantly after TNFα stimulated activation of NF-κB and 
IL-8 production in a dose-dependent manner. Thus, it must be concluded that the 
negative regulatory effect of AUP1 overexpression is not specific for the IL-1/LPS 
signaling pathway.  
Although IL-1/LPS pathway and TNFα pathway utilize distinct signaling 
transduction machinery to exert their functions, all of them lead to the activation of 
NF-κB transcription factor and p38/JNK MAPK in which the activation of NF-κB is 
the hallmark of the inflammatory response [Martin, Wesche – BBA – 2002; 
Verstrepen et. al. – Cellular and Molecular Life Sciences – 2008]. Therefore, the 
involvement of AUP1 in the NF-κB was studied using co-immunoprecipitation 
experiments to verify whether AUP1 interacts with NF-κB p65 and p50 subunits. 
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However, there was no evidence for the physical association of AUP1 and the NF-
κB transcription factor.   
AUP1 associates with components of the IL-1 signaling pathway and seems to be 
involved in the regulation of this pathway. This observation together with the fact 
that AUP1 plays a similar role in TNFα pathway led to the presumption that AUP1 
may interact with components of the TNFα pathway. Accordingly, AUP1 was 
examined for the interaction with three components of the TNFα-induced survival 
pathway including TNFR1, TRADD and TRAF2 by co-immunoprecipitation 
experiments. AUP1 was found to interact with all of three tested molecules of the 
TNFα signaling pathway. However, only TNFR1 interacts strongly with AUP1. 
TRADD and TRAF2 possibly associate with AUP1 indirectly through endogenous 
TNFR1 in HEK293RI cells.  
 
5.5. AUP1 overexpression does not affect STAT-mediated IL-6 signaling 
but AUP1 interacts with an IL-6R component 
From these results, the critical question arises whether AUP1 is only involved in 
signaling pathways of pro-inflammatory mediators such as IL-1β, LPS and TNF-α, 
which all centrally relay on NF-κB, or whether AUP1 plays a more generalized role 
in cellular functions. To clarify this question, the influence of AUP1 overexpression 
on another signaling pathway which is completely different from IL-1, LPS and 
TNFα pathways was examined. The IL-6 pathway appeared to be a good candidate. 
IL-6 cytokine exerts its action via the IL-6 receptor and signal transducer gp130 
leading to the activation of Janus kinases and the phosphorylation and activation of 
the transcription factor STAT3. STAT3, in turn, once phosphorylated, dimerizes, 
translocates to the nucleus, and activates the transcription of its regulated genes 
[Levy, Darnell – Nature Reviews – 2002; Heinrich et. al. – Biochemical Journal – 
2003; Murray – Journal of Immunology – 2007]. Human hepatocarcinoma HepG2 
cells, which respond well to IL-6, were transiently transfected with different 
amounts of a hAUP1 encoding construct. Transfected cells were stimulated with 
rhIL-6 and the signaling performance was evaluated by STAT3-dependent firefly 
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luciferase expression. The result revealed that overexpression of AUP1 did not alter 
the STAT3-driven luciferase activity in HepG2 cells stimulated by IL-6, while, 
similarly to the results observed in HEK293RI cells, overexpression of AUP1 
reduced IL-1β and TNFα-stimulated activation of NF-κB in a dose-dependent 
fashion in HepG2 cells. These results support the working hypothesis that AUP1 is 
involved in some signaling pathways specifically and that overexpression of this 
protein does not cause a global effect to physiology of cells. 
Surprisingly, when association of AUP1 with IL-6Rα and gp130 – the two 
components of the IL-6 receptor complex – was investigated, AUP1 was found to 
associate with one of the two molecules. AUP1 interacted with the non-signaling 
IL-6Rα chain but not with gp130 – the critical signaling transducer of IL-6 pathway 
[Rose-John, Schooltink – Recent Results Cancer Res – 2007]. This finding 
implicated that more work was required to clarify the involvement of AUP1 in the 
IL-6 signaling pathway.  
 
5.6. The biological function of AUP1: A common negative regulator of 
many signaling pathways  
The overexpression of AUP1 reduced IL-1β-, LPS-, TNFα-stimulated NF-κB 
activation and cytokine production, whereas it did not affect to IL-6-induced STAT3 
activation. In order to further address the biological function of AUP1, besides the 
investigation of how AUP1 overexpression affects the interested signaling 
pathways, the influence of AUP1 removal on signaling pathways was investigated. 
Thus, AUP1 expression in HEK293RI and HepG2 cells was knock-downed by 
means of siRNA and the responses of cells to IL-1β, TNFα and IL-6 were 
investigated. IL-1β- and TNFα -induced IL-8 production as well as NF-κB 
activation were enhanced in AUP1 knock-downed HEK293RI cells compared to 
those in control cells. These results, together with the previous data obtained in 
overexpression experiments, provide evidence that AUP1 is an negative regulator of 
signaling transduction induced by IL-1 (LPS) and TNFα. Since AUP1 associates 
with IL-6Rα chain, the involvement of AUP1 in the IL-6 pathway could not be 
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excluded. Here, the involvement of AUP1 with the IL-6 pathway is revealed by the 
increase of IL-6-induced STAT3 activation in AUP1-silenced HepG2 cells 
compared to that in control cells. Therefore, AUP1 may also function as a negative 
regulator of the IL-6 signaling pathway.  
Taken together, AUP1 seems to be a common partial inhibitor of all investigated 
signaling pathways including IL-1β, LPS, TNFα, and IL-6. Moreover, AUP1 
possibly regulates many other signaling pathways. The general negative modulator 
function of AUP1 in the response of cells to stimuli was also manifested by the 
enhancement of stimulation-independent basal IL-8 production, NF-κB and STAT3 
activation in AUP1-silenced cells. The basal NF-κB and STAT3 activation are 
possibly caused by growth factors in culture medium. The increase of basal NF-κB 
and STAT3 activation in AUP1-silenced cells implicates that cells respond to 
growth factors better in the removal of AUP1 or, in another word, AUP1 may be a 
partial inhibitor of growth factor signaling.    
 
5.7. The biological function of AUP1: Overexpression interferes with    
IL-1β and LPS signaling transduction upstream of IκB and JNK/p38 
MAPK 
In the present study, NF-κB - or STAT3-dependent luciferase reporter gene assay 
and IL-8, IL-6 production were applied to study the biological functions of AUP1 in 
IL-1β, LPS, TNFα and IL-6 signaling pathways. Although these read-outs reflect 
the response of cells to stimuli, the underlying mechanism of them is protein 
synthesis of luciferase enzyme or chemokine/ cytokine. Hence, the partially 
inhibitory activity of AUP1 in IL-1β, LPS, TNFα or IL-6 signaling pathways 
suggested by overexpression and silencing of AUP1 experiments is possibly the 
result of either the down-regulation of signaling transduction or the protein 
biosynthesis impairment. To distinguish the possible aspects of AUP1 function, 
kinetics of some important events in IL-1β- and LPS-mediated signaling pathways 
were investigated in cells with and without overexpression of AUP1. The studied 
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events included the phosphorylation and degradation of IκB, phosphorylation of 
JNK, phosphorylation of p38 which are upstream of NF-κB activation and are not 
directly concerned with the protein synthesis process. Overexpression of AUP1 in 
HEK293RI cells resulted in the reduction of IL-1β-induced phosphorylation of 
p38/JNK MAPK and the delay of IκB degradation. Consistent with this, in 
KeratinoRI-/- cells stimulated by LPS, AUP1 overexpression caused the reduction 
of IκB degradation and the delay of p38 phosphorylation compared to those of 
control cells. Furthermore, the IL-1β- and LPS-induced DNA-binding activity of 
NF-κB-p65 was also reduced in AUP1-overexpressed cells compared to that in 
control cells. Taken together, it must be concluded that AUP1 overexpression 
impairs IL-1β and LPS signaling transduction and that the interference happens at 
the level of the activator of IκB: NEMO-IKK complex and the activator of p38/JNK 
MAPK: MKKs or up-stream of them. 
 
5.8. Perspective of the present study 
The results obtained in the present study shed more light on the biological functions 
of AUP1. AUP1 exhibits functional properties of a common negative regulator for 
the response of cells to outside stimuli such as IL-1β, LPS, TNFα, IL-6. It is 
presently unknown whether AUP1 interacts with TLR4, but it is clear that AUP1 
associates with IL-1RI, TNFR1 and IL-6R. Analysis of the influence of AUP1 
overexpression in IL-1β and LPS signaling transductions revealed that AUP1 
interferes with these signaling pathways upstream of the NEMO-IKK complex and 
the p38/JNK MAPK. The fact that IL-1β, TNFα and IL-6 – induced pathways are 
completely distinct, the only thing in common with respect to AUP1 is that all of the 
three receptors IL-1RI, TNFR1 and IL-6Rα associate with AUP1. This raises the 
question whether AUP1 is involved in expression and/or performance of these 
receptors on the cell surface. 
Although it is presently not possible to pinpoint the underlying mechanism of AUP1 
action in these signaling transduction pathways, this work suggests that AUP1 
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down-regulates the response of cells to outside stimuli possibly via the regulation of 
the receptors on the cell surface. There are two hypotheses to explain how AUP1 
interferes with the cell surface receptor functions. First, AUP1 may reduce the 
amount of the receptors expressed on the cell surface by either interfering with the 
trafficking of receptor molecules from the endoplasmic reticulum to the cell surface 
or by enhancing the dislocation/degradation of the receptors from endoplasmic 
reticulum membrane during their synthesis. As reported previously, overexpression 
of the dominant negative form of AUP1, GFP-AUP1, inhibited strongly class I 
MHC heavy chains dislocation and degradation [Mueller et. al. – PNAS – 2008], 
indicating that AUP1 may accelerate the dislocation/degradation of receptor 
components from the endoplasmic reticulum membrane. Obviously, signaling will 
be indeed impaired when the amount of the corresponding cell surface receptors is 
decreased. Second, AUP1 may associate constitutively with components of the 
receptor complexes and obstruct the recruitment to the receptor complexes of 
downstream molecules in the signal transduction machinery. Thus, AUP1 may 
sustain the receptor complexes in inactive states or may attenuate the signaling 
transductions. A similar model for the function of AUP1 was proposed in the case 
of the αIIbβ3 integrin receptor complex in platelet cells, where AUP1 associates with 
the cytoplasmic tail of αIIb subunit thus mantains the αIIbβ3 complex in an inactive 
state [Kato et.al. – JBC – 2002; Kato, Oshimi – Platelets – 2009]. Therefore, the 
subsequent investigations will aim to elucidate the influence of the overexpression 
and removal of AUP1 on the quantity of cytokine receptors such as IL-1RI, TNFR1 
and IL-6Rα expressed on the cell surface. On the other hand, it may be necessary to 
study the effect of AUP1 overexpression and silencing on the formation of these 
active receptor complexes upon cytokine stimulation.                     
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6. SUMMARY 
In the progress of seeking for new partners of IRAK4 - a critical kinase of the        
IL-1R/TLR signaling pathways - using the yeast two-hybrid screening, AUP1 
(Ancient Ubiquitous Protein 1) was identified to interact with IRAK4. AUP1 is a 
protein which is highly conserved in evolution and is ubiquitously expressed in 
tissues of mouse and human. However, the functions of AUP1 in cell biology have 
not been clearly defined yet.  
The interaction of AUP1 was confirmed for the interaction with IRAK4 and IRAK1 
in HEK293RI cells. Interestingly, AUP1 was only found to interact with kinase 
inactive IRAK4 and IRAK1 but not with the wild type molecules, indicating that the 
kinase activity of IRAK molecules interferes with their association with AUP1. In 
addition, AUP1 can be phosphorylated by IRAK4 and possibly IRAK1 as shown in 
the forced co-immunoprecipitation and in vitro kinase assays. Besides IRAK4 and 
IRAK1, AUP1 interacts with other components in the IL-1 signaling machinery 
such as IL-1RI, MyD88, Tollip, TRAF6, suggesting the involvement of AUP1 in the 
IL-1 pathway.  
Indeed, overexpression of AUP1 in HEK293RI and KeratinoRI-/- cells reduces IL-
1β- and LPS-induced activation of NF-κB as well as chemokine/cytokine 
production, respectively. However, the regulatory effect of AUP1 overexpression is 
not specific for IL-1 or LPS signaling as TNFα signaling is also impaired by AUP1 
overexpression. AUP1 was also found to associate with TNFR1, TRADD and 
TRAF2 which are components of TNFα pathway. Interestingly, although 
overexpression of AUP1 does not affect STAT-mediated IL-6 signaling, AUP1 
interacts with the IL-6Rα chain but not with the signaling transducer gp130. In 
contrast, silencing of AUP1 via siRNA enhances the IL-1β-, TNFα-stimulated 
activation of NF-κB as well as IL-6-stimulated activation of STAT3, indicating that 
AUP1 is a common negative regulator of the cytokine signaling pathways 
investigated.  
As overexpression of AUP1 interferes with IL-1β/LPS signaling transduction 
upstream of IκB and the JNK/p38 MAPK and AUP1 was found to associate with all 
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three of the cytokine receptors IL-1RI, TNFR1 and IL-6Rα, the role of AUP1 may 
be to down-regulate the response of cells to outside stimuli via the impairment of 
the expression and/or performance of these receptors on the cell surface. 
 
7. ZUSAMMENFASSUNG 
Im Rahmen der Suche nach neuen Wechselwirkungspartnern von IRAK4 –einer 
kritischen Kinase des IL-1R/TLR Signalwegs- wurde mit dem “yeast two hybrid”-
System AUP1 (Ancient Ubiquitious Protein 1) als Partner von IRAK4 identifiziert. 
AUP1 ist ein Protein, das in der Evolution stark konserviert ist und ubiquitär in 
Geweben der Maus und des Menschen exprimiert wird. Die Funktionen von AUP-1 
in der Biologie der Zelle sind bis heute weitgehend ungeklärt.  
Die direkte Proteinwechselwirkung von AUP1 mit IRAK4 und IRAK1 wurde in der 
Zelllinie HEK293RI nachgewiesen. Interessanterweise konnte AUP1 nur  mit den 
Kinase-inaktiven Varianten von IRAK4 und IRAK1 immunpräzipitiert werden, 
jedoch nicht mit den Wildtyp-Molekülen, was darauf hindeutet, dass die 
Kinaseaktivität der IRAK-Moleküle mit der Assoziation von AUP1 interferiert. 
Zusätzlich konnte durch forcierte Koimmunpräzipitationen mit anschließendem in 
vitro Kinase Assay gezeigt werden, dass AUP1 durch IRAK4, und möglicherweise 
auch durch IRAK1, phosphoryliert werden kann. Neben IRAK4 und IRAK1 
interagiert AUP1 mit weiteren Komponenten der IL-1 Signaltransduktions-
maschinerie wie z.B. IL-RI, MyD88, Tollip, TRAF6, was nahe legt, dass AUP1 im 
IL-1 Signalweg eine Rolle spielt.  
Überexpression von AUP1 in HEK293RI und KeratinoRI-/- Zellen verringerte die 
IL-1β- oder LPS-induzierte Aktivierung von NF-κB genauso wie die Chemokin/ 
Zytokinproduktion. Dieser negativ regulatorische Effekt der Überexpression von 
AUP1 ist jedoch nicht spezifisch für die IL-1 oder die LPS Signaltransduktion, da 
die durch TNFα ausgelösten Signale ebenfalls durch AUP1 Überexpression 
beeinflusst wurden. AUP1 assoziierte auch mit TNFR1, TRADD und TRAF2; alle 
drei Moleküle sind Bestandteile des TNFα-Signalwegs. Die Überexpression von 
AUP1 beeinflusste die STAT-vermittelte IL-6 Signaltransduktion zwar nicht, 
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dennoch konnte gezeigt  werden, dass AUP1 an die IL-6 Rezeptor α-Kette bindet, 
jedoch nicht an der signaltransduzierende gp130 Untereinheit. Im Gegensatz zur 
Überexpression, verstärkte das Ausschalten von AUP1 mittels siRNA-Technik die 
IL-1β- und TNFα-stimulierte Aktivierung von  NF-κB ebenso wie die IL-6-
stimulierte Aktivierung von STAT3. Dies weist darauf hin, dass AUP1 ein 
generalisierter negativer Regulator der hier untersuchten Zytokinsignalwege ist. Da 
die Wirkung der Überexpression von AUP1 im IL-1β/LPS Signalweg oberhalb von 
IκB und dem JNK/p38 MAPK – Element einzuordnen war und zudem AUP1 an den 
drei untersuchten Zytokinrezeptoren IL-1RI, TNFR1 and IL-6Rα nachgewiesen 
werden konnte, liegt es nahe zu vermuten, dass die Rolle von AUP1 darin liegt, die 
Fähigkeit einer Zelle zu dämpfen, auf Stimuli von außerhalb der Zelle zu antworten, 
indem die Expression oder Funktionsfähigkeit dieser Rezeptoren auf der 
Zelloberfläche negativ reguliert wird. 
(D. Q. N. was assisted in translating the English summary into the German 
Zusammenfassung by Prof. M. U. Martin.)   
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